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ABBREVIATIONS
ADH Antidiuretic hormone
ADP Adenosine 5 1-diphosphate
AMP .Adenosine 5 1-phosphate
ATP Adenosine 5'-triphosphate
BBOT 2,5-bis (5t butyl benzoxazole 2 thiophene)
CNS Central Nervous System
CSF Cerebrospinal Fluid
Cyclic AMP Adenosine 3 ’:5’-cyclic phosphate
Cyclic 2 ’3'AMP ' Adenosine 2»:3f-cyclic phosphate
Cyclic CMP Cytidine S ’rS^cyclic phosphate
Cyclic GMP Guanosine 3 ’:5'-cyclic phosphate
Cyclic IMP Inosine S ’iS’-cyclic phosphate
Cyclic TMP Thymidine 3.1'^-cyclic phosphate
Cyclic IJMP Uridine 3 * : 5' -cyclic phosphate
Dopa 3,4-dihydroxyphenylalanine
GMP Guanosine 5 ’-phosphate
G6PD Glucose-6-phosphate dehydrogenase
5HIAA 5-Hydroxyindoleacetic acid
HVA Homovanillic acid
LSD Lysergide
NADP+ Nicotinamide adenine dinucleotide phosphate
Pi Orthophosphate (inorganic)
PMN Phenylmercuric nitrate
PPi Pyrophosphate (inorganic)
RTA Road Traffic Accident
TSH Thyroid stimulating hormone
ABSTRACT
The biological function, metabolism and excretion 
of cyclic AMP are reviewed. The effects of drugs on cyclic 
AMP metabolism are considered and the methods that have 
been used to assay cyclic AMP are summarised. The 
selected binding protein assay was modified slightly 
so that incubation could be carried out at room 
temperature. 70 drugs of wide ranging pharmacological 
action were tested as potential inhibitors of 
phosphodiesterase and the relevance of this inhibition to 
the situation in vivo is discussed. i
Cyclic AMP was stable in vitro in urine samples 
stored at room temperature, 4°C and -20°C for at least 2 
days, 1 month and 3 months respectively. A phenyl mercuric 
nitrate and sodium fluoride tablet preserved cyclic AMP 
levels at room temperature for at least 6 weeks. Cyclic 
AMP was also stable in a bladder stored at 4°C for up to 
3 days.
Urine flow rate did not affect cyclic AMP excretion. 
The urinary cyclic AMP to creatinine ratio was found to 
have a higher mean value in women than in men (ie 4.3 as 
opposed to 2.9nmols/mg). The variation of the ratio was 
very similar for both sexes (ie coefficients of variation 
of 25% and 27% for men and women respectively).
Two subjects were used as a screen to determine which 
factors influenced cyclic AMP excretion. In both subjects 
24 hourly cyclic AMP excretion (coefficients of variation of 
7% and 14%) and the cyclic AMP to creatinine ratios 
(coefficients of variation of 15% and 18%) were reasonably
constant. A slight diurnal variation- was observed for 
both subjects. Urinary pH, exercise, alcohol, vitamin C 
and therapeutic doses of amphetamine, amylobarbitone,
;imipramine and trifluoperazine had no significant 
effects on cyclic AMP excretion.
The variation in creatinine excretion is considered 
and disease states that affect both creatinine and cyclic 
AMP excretion are discussed.
Dying and the associated physical and biochemical 
changes are described. Poisoning by drugs and the use of 
potential biochemical markers of drug overdosage are 
discussed.
Post mortem urines from natural deaths could not 
be distinguished from drug overdose victims in terms of the 
cyclic AMP to creatinine ratio. In both cases, however, 
there was considerably greater scatter than in urines 
obtained from living persons.
Post mortem cyclic AMP levels were not effective 
markers of drug overdosage. However,the cyclic AMP 
excretion data may be of use in a clinical context and 
possible applications are discussed.
SECTION 2 
INTRODUCTION
2. INTRODUCTION
2.1 Cyclic Adenosine 3'5' Monophosphate
Studies on the mechanism of glycogen breakdown in 
liver, by Earl Sutherland and co-workers, led to the dis­
covery of a low molecular weight, heat stable compound 
that increased glycogenolysis in cell free extracts 
(Sutherland et al., 1957; Sutherland and Rail, 1958a).
This promoting factor was later identified as cyclic AMP 
(Fig 1; Lipkin et al., 1959).
Adenosine triphosphate is converted to cyclic AMP by 
the enzyme adenyl cyclase which occurs in the plasma mem­
brane (Sutherland et al., 1962). A phosphodiesterase, 
generally found in the soluble fraction of the cell, hydro­
lyses cyclic AMP to 5' AMP (Sutherland and Rail, 1958b). 
Thus the main components of the cyclic AMP system can be 
represented by the following equation:
adenyl cyclase phosphodiesterase
ATP -------- :------E? cyclic AMP ------------------ E> 5* AMP
Mg2+ ppi Mg2+
• * 
Sutherland’s group found cyclic AMP and adenyl cyclase in
most animal cells and many hormones appeared to alter both
the concentration of cyclic AMP and the activity of the
adenyl cyclase in their target tissues (Table 1). The
’’two messenger theory” of hormone action was developed
from the above evidence (Sutherland et al., 1965).
The hormone, acting as the first messenger, circulates 
in the blood and binds to the receptor on the plasma mem­
brane of the target cell, activating adenyl cyclase within
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the membrane. Cyclic AMP, the second messenger, is then 
manufactured within the cell, leading to the appropriate 
physiological response (Figs 2 and 3). It is suggested 
that the response is. initiated by the phosphorylation of 
one or more cell proteins. .
Sutherland et al. (1962) established that in most
* ’ . '
mammalian cells adenyl cyclase activity occurs in- the 
crude nuclear fraction. This fraction had previously
been shown‘to contain cell membrane as well as nuclear
\ .■ i
material (Neville, 1960). A  pressure homogeniser, which 
fragmented cell membranes with little damage to nuclei, 
allowed the two - materials to be separated and indicated 
that adenyl cyclase activity was in fact associated with 
the cell membrane fraction (Davoren and Sutherland, 1963). 
In further experiments ((/)ye and Sutherland, 1966), which 
involved proteolytic enzyme denaturation of extracellular 
enzyme systems, it was concluded that adenyl cyclase 
activity was located on the inside of cell membranes. In 
agreement with Davoren and Sutherland (1963), the recent 
studies of Wisher and Evans (1975) showed that the highest 
glucogen stimulated adenyl cyclase -activity was associated 
with a light plasma membrane subfraction. A sucrose 
gradient flotation technique was used to separate the 
plasma membrane from a microsomal and nuclear pellet.
The.isolation of a highly purified adenyl cyclase 
system has not yet been accomplished. However, a soluble 
bacterial adenyl cyclase has been purified extensively 
(Hirata and Hayashi, 1967). Whether or not this is
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related to the enzyme in eukaroytes remains unestablished. 
One would anticipate that the enzyme found in higher forms 
would have differing properties in that compartmentalisa- 
tion, ie membrane localisation, is essential for function.
Evidence that hormones bind to adenyl cyclase has 
been found by several groups of workers. Bitensky et al. 
(1967) and Cohen and Bitensky (1969) showed that activa­
tion of liver adenyl cyclase by glucagon in vitro was not 
suppressed by subsequent washing of the particulate enzyme,
it
which suggests that firm binding occurs between glucagon 
and its receptor. Similarly TSH activation of thyroid 
adenyl cyclase (cell suspensions) was not reversed by 
washing with buffer, but could be removed by TSH antibody 
(Pastan et al., 1966). These observations indicate that,- 
in addition to firm binding, the hormone acts at the sur­
face of the cell. Ilofman (1962) suggested that basic 
amino acid sequences are important for receptor binding. 
However, little is. known about the mechanism of hormone 
removal from the receptor. Phospholipids have been shown 
to affect binding as adenyl cyclase activity and glucagon 
stimulation were lost by exposing the membranes to phospho- 
lipase C. The loss of enzyme activity could be partially 
reversed by the additipn of phospholipids (Rodbell et al. , 
1970).
Fat cell ghosts contain a cyclase which can be acti­
vated by at least 6 hormones: adrenocorticotrophin,
glucagon, secretin, luteinising hormone, thyrotrophfn and 
catecholamines (Birnbaumor e t a l ., 1969). These hormones
act through a receptor site, but the method of activation 
of the cyclase by the receptor has not yet been estab­
lished. An allosteric activation of the cyclase would 
be the simplest mechanism. In the fat cell, cyclase 
activity was not additive as the cyclase was exposed to 
each of the hormones, which suggested a common catalytic 
site. Birnbaumer et al. (1969) proposed'that these
hormones activated the cyclase by .facilitating the effect 
of magnesium on the enzyme (ie, a high concentration of 
magnesium negated the hormone effect). This explanation 
was not applicable to the stimulation of hepatic cyclase 
by either glucagon or adrenaline (Gorman and Bitensky, 
1970). Regulation of adenyl cyclase activity did not 
appear to be a simple function of the circulating hormone 
concentration, as guanyl nucleotides and both calcium and 
magnesium ions were also found to regulate cyclase acti­
vity (Rodbell et al., 1970; Rodbell, 1971).
Fluoride activates several adenyl cyclase systems 
but the mechanism differs from that of hormones in that 
fluoride is unable to stimulate cyclic AMP formation in . 
intact cells (Sutherland et al., 1962). The properties 
of adenyl cyclase in preparations from mammalian tissues 
were indicative of a lipoprotein structure (Sutherland 
et al., 1962; 0ye and Sutherland, 1966).
A phosphodiesterase, capable of destroying the biolog 
ical action of cyclic AMP, was found in extracts of heart 
brain and liver by Sutherland and Rail (1958b)* The 
enzyme from dog heart was purified and the product of the
esterase reaction was shown to be AMP. Phosphodies­
terase was identified in a great' many of the dogs tissues 
(Table 2). Phosphodiesterases are present in nearly all 
mammalian tissues (Cheung, 1970; Appleman e.t al. , 1973; 
Kher and Anand, 1972), bacteria (Nielson et al., 1973;
Brana and Chytil, 1966), insects (Morishima, 1973), higher 
plants (Bonner et al., 1969) and marine organisms (Yamamoto 
and Massey, 1969). The enzyme is found in the soluble 
fraction of most tissues. However, in the central nervous 
system a large proportion appears to be particulate and may 
be associated with nerve endings, post synaptic membranes 
(De Robertis et al., 1967; Cheung and Salganicoff, 1967) 
and synaptasomes (Thompson and Appleman, 1971).
Purified, soluble fraction, beef heart phosphodies­
terase appears to be specific for purine 3 15 f mononucleo-. 
tides and is apparently inactive against 2'3'AMP (Butcher 
and Sutherland, 1962; Nair, 1966). Drummond and Perrott 
Yee (1961) found that rabbit brain•phosphodiesterase 
required Mg2* although Co2* and Mn2* could produce partial 
activation. These authors also found that Mg2+ at a con­
centration above O.SmM was - inhibitory. Cheung (1967) 
reported that Mn2* could completely and Co2+ and Ni2+ 
partially replace Mg2+ in the activation of rat brain 
phosphodiesterase; ATP and citrate were found to be inhib­
itory. Cheung suggested that this phosphodiesterase, in 
its active form, behaves as a metalloenzyme complex and 
that ATP and citrate were acting as Mg2* chelators.
Table 2
Distribution of Cyclic Nucleotide Phosphodiesterase
in Dog Tissue
Tissue Units*per g (wet weight)
Brain cortex 1233
Brain stem 455'
Adrenal 364
Kidney medulla j 220
Kidney cortex 176
Small intestine (whole) 167
Cardiac ventricle 156
Spleen 128
Liver 120
Pancreas 120
Cardiac auricle 116
Cerebellum 88
Lung 84
Testis * 74
Sartorius muscle 48
Aorta 44 ‘
Femoral artery 37
Diaphragm muscle 32
Femoral nerve 17
Ref: Butcher and Sutherland, (1962).
* Units - Amount of enzyme causing the destruction of 
lymol of adenosine S ’S'-cyclic phosphate in 30 minutes 
at 30°C.
It is interesting to note that insulin increases 
phosphodiesterase activity in rat fat cells and this may 
be a mechanism by which insulin lowers cyclic AMP levels 
in these tissues (Loten and Sneyd, 1970). Evidence of 
endogenous activation of phosphodiesterase, has also been 
presented by Cheung (1971) who described a protein acti­
vator in bovine brain. •
Monn and Christiansen (1971) demonstrated 7 different 
fqrms of phosphodiesterase in rat and rabbit tissue using 
starch gel electrophoresis. Pichard et al. (1973) have 
also found that human blood platlet phosphodiesterase 
consists of 2 forms which are separated readily by elec­
trophoresis. The 2 enzymes have different Km values and 
inhibition properties. The 2 Km values are in close 
agreement with those of the platlet phosphodiesterase 
described by Song and Cheung (1971). The latter authors 
suggested that the low Km enzyme may be responsible for 
hydrolysing.cyclic AMP under basal•conditions, with the 
high Km enzyme becomming operative when the cell is con­
fronted with a surge of cyclic AMP, eg after hormonal 
action. A phosphodiesterase with '2 Km values has also 
been found in bovine heart (Beavo et al., 1970). A gel 
filtration, column chromatography technique was used to 
separate two phosphodiesterase enzymes from both rat brain 
and beef heart (Kakiuchi et al., 1971; Hrapchak and 
Ramussen, 1972). Human brain phosphodiesterase, however,
exhibited only 1 Km value (Kodama et al., (1973).' .
Cyclic GMP was reported to stimulate the action of 
cyclic AMP phosphodiesterase (Beavo et al,, 1970), This 
raises the possibility that cyclic GMP may control cyclic 
AMP through both adenyl cyclase and phosphodiesterase.
It is not possible, at present, to explain all the 
effects of cyclic AMP in terms of only one or a few basic 
actions. The most thoroughly investigated effect has been 
phosphorylase activation in skeletal muscle (Krebs et al., 
1966). ‘The process involves the allosteric stimulation 
of a protein kinase which catalyses the phosphorylation and 
hence activation of phosphorylase kinase. This in turn 
catalyses the activation of phosphorylase by phosphoryla­
tion (ie a cascade effect), A similar series of reactions 
appears to be involved when cyclic AMP inactivates 
glycogen synthetasein this case phosphorylation produces 
a less active enzyme (Reimann and Walsh, 1970). In both 
cases cyclic AMP interacts with a regulatory unit of a 
kinase, which results in either the stimulation or. 
inhibition of the catalytic unit of the enzyme.
In addition to its cytoplasmic effects cyclic AMP 
also appears to influence events- in the nucleus. It 
catalyses the synthesis of $-galactosidase in 
Escherichia coli by acting at the level of gene 
transcription (Pastan and Perlman, 1968) and Kuo and 
Greengard (1969) describe a cyclic AMP stimulated protein 
kinase capable of phosphorylating histones.
The numerous reported actions of cyclic AMP may 
all be initiated by the phosphorylation of a protein. 
However, to date, little is known about this initial 
step.
2.2 The Measurement of Cyclic AMP
Cyclic'AMP. was originally estimated by its ability to 
convert inactive phosphorylase to the active enzyme in 
liver slices (Sutherland and Rail i 1958a). Unfortunately, 
the response was non-linear and the assay was insuffici­
ently sensitive to measure endogenous levels of cyclic AMP. 
Interfering substances.also presented a serious problem.
The next intrinsically different method for measuring 
cyclic AMP was based on a fluorometric cycling technique 
in which cyclic AMP was separated from other adenosine 
nucleotides and converted to 5 1 AMP by phosphodiesterase.
This 5*AMP.was subsequently converted to ADP by myokinase 
and then, employing an ATP generating (phosphoenol pyru­
vate and pyruvate kinase) and utilising system (glucose, 
hexokinase, G6PD and NADP+), NADPH was formed and measured 
fluorometrically (Breckenridge, 1964>. The rate of pro­
duction of NADPH is dependent upon the amount of cyclic AMP 
in the original sample. The method is very sensitive, ie 
5 x 10“11}mols of cyclic AMP can be detected. Johnson et al.
(1970) devised.a similar method in which ATP, derived from 
cyclic AMP, was measured by means of a luciferase luciferin 
reaction. The reaction is linear over 3 orders of magni­
tude and can detect 1 x 10~15mols. of cyclic AMP. 
Unfortunately, the last 2 methods require lengthy purifica­
tion procedures.
Physiochemical methods have also been employed for 
cyclic AMP estimation. A gas chromatographic method 
(Krishna, 1968) separated cyclic nucleotides but was too
insensitive for biological samples. Brooker (1970) util­
ised a high pressure ion exchange method which detected 
picomole amounts of cyclic AMP but had problems of 
specificity.
Radioactive labelling has proved extremely useful in
cyclic AMP estimation. Brooker et al. (196.8) devised an
. ) '
isotope dilution method which relied on the competition 
between labelled and unlabelled (from sample) cyclic AMP 
for the hydrolytic site of brain phosphodiesterase. The 
5*AMP released was dephosphorylated and the nucleoside
i
isolated by an ion exchange resin before counting. The 
number.of counts were inversely proportional to the concen­
tration of the cyclic AMP in the sample. Wastila et al.
(1971) and Kuo and Greengard (1970) measured cyclic AMP by 
determining the amount of 32Pi incorporated into protein,
*by phosphorylase kinase kinase, and found it to be linearly 
dependent upon the cyclic AMP concentration. Radioimmuno­
assays have also been developed for cyclic AMP in which 
labelled and unlabelled cyclic AMP compete for the antibody 
(Steiner et al., 1969). The method was reported to be 
sensitive to 1 - 2pmols of cyclic AMP.
A protein binding assay was utilised in this study.
The assay relies on competition between labelled and 
unlabelled cyclic AMP for the binding site of a naturally 
occurring protein, probably the regulatory unit of. a pro­
tein kinase. The binding protein used was extracted from 
bovine adrenals (Brown et al., 1971). Unbound nucleotide 
is removed from the assay medium by charcoal and the
labelled nucleotide attached to the binding protein is 
counted. The number of counts is inversely proportional 
to the cyclic AMP concentration in the sample. The assay 
is rapid, simple, sensitive (approximately 1 pmol) and 
specific for cyclic nucleotides (see section 4.3). A 
cyclic AMP binding protein has also been extracted from 
skeletal muscle (Gilman, 1970). The advantage a-binding 
protein assay has over radioimmunoassay is that it is far 
easier to extract binding protein than produce antibodies 
for cyclic AMP.
2.3 Cyclic AMP in Urine
Butcher and Sutherland (1962) were the first to 
observe that large amounts of cyclic AMP are excreted in 
human urine. Their subjects excreted from 2 - Yymols in 
24 hours. It has also been possible to detect cyclic GMP 
in human urine (Price et a1 ., 1967). Other in vestigators 
looked for cyclic pyrimidine and 5 ’nucleotides in urine, 
but have concluded that they are absent or present in too 
low a concentration to be detected (Arnold and Price, 1963 
Goldberg et al., 1969). From a study of cyclic AMP
j. •
excretion in humans Broadus et al. * (1970a) drew several 
important conclusions.
(1) Cyclic AMP is not detectably bound to plasma 
proteins and is cleared from plasma by glomerular 
filtration, as the clearance rate of administered 
cyclic AMP is the same as that of inulin.
(2) Urinary cyclic AMP' is derived from both the 
plasma and the kidney. Measurements of inulin 
clearance, and the dilution of the specific activity
of the tracer in the urine, indicated that the kidney 
could contribute from 18 to 52% of the endogenous 
urinary cyclic AMP (an average of 39% was observed).
(3) From isotopic disappearance curves and extra­
cellular volume determinations, it was postulated 
that some miscibility between extracellular and 
intracellular pools of nucleotide occured.
(4) Constant infusion and injection studies of 
tritiated cyclic AMP showed that the nucleotide was 
rapidly removed from the plasma, A half life of 
approximately 32 minutes was derived from exponential 
decay curves. Four-fifths of the cyclic AMP was 
eliminated from plasma by extrarenal clearance (to 
what extent this is due to metabolism, eg hepatic, or 
other excretion processes is unknown). Hence only 
one-fifth of the dose appeared in the urine. The 
endogenous plasma concentration was relatively con­
stant during the course of any one study, ie the
‘ plasma pool must be in a dynamic state.
To date the major sources of urinary cyclic AMP are 
unknown. Chase and Aurbach (1967) found that parathyroid 
hormone injection produced an enormous increase in the 
urinary excretion of cyclic AMP in the rat. Their experi­
ments further suggested that the effect of the hormone was 
on the kidney, as clearance of injected radioactive cyclic 
AMP from the plasma was unaffected. Kaminsky et al.
(1970a) reached a similar conclusion. The latter authors 
showed that it was possible to decrease nephrogenous 
cyclic AMP by calcium infusion, however, the cyclic AMP/ 
inulin ratio could never be brought to unity, ie the
kidney was still contributing to cyclic AMP production.
It could be that, either, parathyroid hormone was not 
completely suppressed or.the kidney produced some cyclic. 
AMP via a mechanism which is independant of the hormone. 
Supporting a parathyroid effect on cyclic AMP excretion, 
it has been observed that 24 hourly urinary cyclic AMP 
excretion was elevated in hyperparathyroidism (Kaminsky 
et al., 1970a; Taylor et al., 1970) and depressed in 
patients with hypoparathyroidism (Chase et al., 1969; 
Taylor et al., 1970). Chase and Aurbach (1967) origin­
ally suggested that parathyroid hormone affects the 
adenyl cyclase system in the kidney, and subsequently 
showed that the cause o f .pseudohypoparathyroidism was a 
lack, or defective form, of parathyroid hormone sensitive 
adenyl cyclase in the kidney. The proportion of urinary 
cyclic AMP, excreted by the kidney in humans, which is 
directly attributable to parathyroid hormone is unknown. 
Thyrocalcitonin administration has resulted in increased ; 
urinary cyclic AMP, but this is apparently due to an 
increased plasma level (Kaminsky et al., 1970b). ■ Reports
concerning antidiuretic hormone have been contra­
dictory. Takahashi et al. (1966) reported that patients
with diabetes insipidus excreted low amounts of cyclic AMP 
which could be increased by ADH administration. Davis 
et al. (1969) and Taylor et al. (1970) also reported
that ADH administration increased cyclic AMP excretion in 
man, whereas, Chase et al. (1969) and Kaminsky et al.
(1970b) could detect no effect of ADH on cyclic AMP in 
humans. At present the role of ADH in controlling cyclic
AMP levels is not clear. There have been many reports 
which indicate possible sources of plasma cyclic AMP. 
Broadus et al. (1969;- 1970b) showed that plasma levels 
of cyclic AMP could be increased in response to glucagon 
administration, resulting in increased urinary excretion. 
Glucagon stimulates liver adenyl cyclase and raised levels 
of cyclic AMP can be detected in the perfusate from 
isolated livers.
Catecholamines are also able to influence plasma 
and urinary cyclic AMP (Broadus et al., 1970b; Kaminsky 
et al. , 1970b; Ball et al,, 1972). Beta-adrenergic 
stimuli were shown to increase plasma cyclic AMP and 
this response was prevented by beta-blocking agents. 
However, contributions to in vivo urinary levels of 
cyclic AMP by glucagon or catecholamines have not been 
ascertained. .
. Generally research workers have been fairly 
consistent in their reports concerning the daily 
excretion of cyclic AMP (Table 3). Taylor et al, '
(1970) found no significant difference in the 24 hourly 
excretion of cyclic AMP for men and women under or over 
the age of 50. These authors also observed increases 
in 24 hourly cyclic AMP excretion (20 - 40%) during the 
midportion of the menstrual cycle and also 30 weeks 
after gestation. In a later report August and Hung 
(1973) observed no correlation between age and 24 hourly 
urinary cyclic AMP excretion,(pmols/m2 of body surface 
area), in children and adolescents, Endocrinological 
disorders would, na/turally, be one sphere where 
alterations in cyclic AMP excretion might be
expected. In several patients with untreated diabetes
Table 3
i
24 Hourly Cyclic AMP Levels
24 Hourly Excretion 
(ymols) 
range or (±SD)
Reference
2 - 7 
4.2 - 6.1 
3.5 ± 0.2 
5.64 ± 0.7 
1.4 - 3.2
Butcher and Sutherland (1962) 
Takahashi, et al. (1966) 
Taylor, et al. (1970)
Paul, et al. (1970a)
Abdulla and Hamadah (1970)
mellitus 24 hourly cyclic AMP excretion was significantly 
higher than normal levels and there was a decrease of 
up to 50% excretion after insulin treatment, (Tucci 
et al. , 1973). Patients suffering from thyrotoxicosis 
(who have high blood levels of long acting thyroid stimu­
lating hormone) excreted high 24 hourly urinary levels of 
cyclic AMP (Levey and Pastan, 1970). Lin et al, (1973) 
have also noted high urinary cyclic AMP/creatinine ratios 
(24 hourly) in hyperthyroidism (means of 6.8nmols cyclic 
AMP/mg creatinine occurred in both male and female com­
pared with normal values of 3.2 and 3.8nmols/mg respect­
ively). Decreased rates of urinary cyclic AMP excretion 
in asthmatics, compared with normal subjects, have been 
observed (Bernstein et al., 1970).
The unusual secretion of sodium and fluid into the 
gastrointestinal tract in cholera has been attributed to 
over stimulation of intestinal cyclase by cholera toxin 
(Schafer et al., 1970; Hirschorn and Greenough, 1971).
It was postulated that the regulatory and catalytic adenyl 
cyclase units were uncoupled and consequently, the inhib-
j
itory effect of the regulatory unit was lost. Taylor 
et al. (1970) noted that 24 hourly cyclic AMP excretion
was very low in certain kidney diseases (pyelonephritis and 
glomerulonephritis) the excretion in these patients being 
one-seventh of the normal 24 hourly urinary level.
The 24 hourly excretion of cyclic AMP was found to 
have decreased in late untreated toxaemia of pregnancy, 
ie one half the value in normal pregnancy (Raij et al. ,
1973).
Cancer (Emmelot and Bos, 1971; Tomasi et al.-, 1973) 
and psoriasis (Wright .et al., 1973) have also been associ­
ated with low tissue levels of cyclic AMP, which again 
could be reflected in a decreased urinary excretion.
Cyclic AMP and Psychotic Disorders ' f ..
In 1970, Abdulla and Hamadah and Paul et al. (Table 4) 
reported low levels of 24 hourly urinary cyclic AMP excretion 
in endogenous depression, compared with a control group. 
Increased levels were also observed in manics. . The 24 
hourly levels noted by Abdulla and Hamadah were normal
1.4 - 3.2ymols, depressed less- than lymol and hypomanics 
greater than 3.4'ymols. They suggested that the symptoms 
of depressive illness reflected a general decrease in 
level of cellular cyclic AMP, including the cells of the 
central nervous system. • These authors further reported 
that the amount of 24 hourly urinary cyclic AMP excreted 
changes towards a normal level as the clinical condition 
improves. Other evidence in support of their hypothesis; 
was that (a) antidepressants inhibit cyclic AMP degradation 
and (b) even though animal experiments are clearly diffi­
cult to set up in this field of study, cyclic AMP reversed 
reserpine induced ptosis in mice (a popular model for 
depres'sion).
A later paper by Paul et al. (1970b) showed that . 
L-dopa (a precursor of catecholamines) increased urinary 
cyclic AMP in depressed patients. The cyclic AMP excre­
tion decreased proportionally as the L-dopa dosage was 
lowered. The depressed patient who showed the greatest
Table 4
24 Hourly Cyclic AMP Excretion Levels
and Corresponding Clinical States
Category Urinary Cyclic AMP . (ymols/24 hours)*
N o . of 
Patients
Psychotic depression 3.4 - 3.8 7
Normal 5.0 - 6.3 10
Neurotic depression 6.3 - 7.1 25
Manic 8.0 -  12.0 ' 5
* All figures mean ±SEM ' 
Ref: Paul et al., (1970a).
improvement had the greatest increases in urinary cyclic 
AMP excretion. These authors also -stated that lithium 
carbonate- treatment, when it improved the condition of 
manics and depressives showed decreases and increases 
respectively in urinary cyclic AMP excretion. Paul et al. 
(1971a.) hypothesised that a marked increase in cyclic AMP 
excretion, noted on the day of a switch from a depressive 
to a manic phase, may serve as a trigger for the increase 
in catecholamines. In a more recent report (Sinanan 
et al., 1975) both endogenous and neurotic depressives 
were observed to'*'have significantly lower 24 hourly cyclic 
AMP excretion than control subjects. Controls, neurotic 
and endogenous depressives excreted 3.98, 2.27 and 2.88 
ymols cyclic AMP/24 hours respectively and the excretion 
of the depressives returned to control levels as patients 
respondedtotrcatment.
Not all papers published support this relationship 
between depressive illness and cyclic AMP excretion.
Jenner et al. (1972) found no consistent correlation
between cyclic" AMP excretion and manic depressive illness' 
in a number of patients studied. However, in one case 
they observed a very marked correlation, which they sug­
gested was the result of a pituitary or hypothalamic 
defect. This they said could explain other cyclical 
changes observed, eg water balance, electolytes. Berg 
and Glinsmanni (1970) stated that Abdulla and Hamadah’s 
observations only supported a correlation between the 
symptoms of depression and factors regulating cyclic AMP 
excretion. They suggested that lowered urinary excretion 
may be a result of low physical activity.
In agreement with Berg and Glinsmanns (1970) postulate 
that physical exercise may affect cyclic AMP excretion, 
Eccleston' et al. (1970) demonstrated that 2-4 hourly urin­
ary cyclic AMP excretion could be affected by exercise. 
Excretion was almost doubled in 2 of the walkers involved 
in their experiments. However, other workers have 
observed no correlation between urinary cyclic AMP excre­
tion and exercise (Paul et al., 1971b; Murad and Pak,
1972; Sinanan et al., 1975).
To conclude, the urinary level of cyclic AMP must be 
interpreted with a great deal of. caution since, at present, 
the factors responsible for basal urinary levels are 
unknown.
2.4 Cyclic AMP and Drugs
There have been extensive investigations of the 
effects of drugs on the cyclic AMP system. Many of the 
earlier studies were concerned with the inhibition of 
phosphodiesterase.
Butcher and Sutherland (1962) found that theophylline 
was a competitive inhibitor of beef heart phosphodiesterase. 
Later investigators showed that caffeine non competitively 
inhibited dog heart phosphodiesterase (Nair, 1966) and com - 
petitively inhibited brain phosphodiesterase (Cheung, 1967). 
Caffeine and theophylline inhibition of phosphodiesterase 
is not entirely unexpected as both resemble cyclic AMP in 
structure. The effect of a series of theophylline deriva­
tives, with substituents in the 8 position, on beef heart 
phosphodiesterase has been evaluated (Goodsell et al., 1971).
Inhibition was markedly influenced by water and lipid 
solubility as well as by size and configuration of the 
substituents. The n-methyl to n-hexyl; cyclo propyl, 
cyclo butyl, cyclo pentyl; isopropyl and isobutyl deriva­
tives were all more potent inhibitors than the parent drug.
Phenothiazines and reserpine (both tranquillisers)
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were found to be potent inhibitors of beef brain and heart 
phosphodiesterase activity, both showing a greater degree 
of inhibition towards the brain enzyme (Honda and Imura, 
1968). Chlorpromazine and -the tricyclic antidepressants 
(desipramine, imipramine and nortriptyline) inhibited phos­
phodiesterase in homogenates of mouse brain (Roberts and 
Simonsen, 1970). The authors suggested that the pharma­
cological action of these antidepressants may be attribu­
table to their effects on the metabolism of cyclic AMP.
In contrast, a series of imidazole compounds (Roberts and 
Simonsen, 1970) and nicotinic acid (Nakano, 1970) were 
found to stimulate phosphodiesterase.
Ramsden (1970) showed that a series of tricyclic 
antidepressants and chlorpromazine inhibited beef heart 
phosphodiesterase and, in agreement with Roberts and 
Simonsen (1970), suggested that the in vivo action of these 
antidepressants could be explained by increases in cyclic 
AMP levels. This was consistent with Abdulla and Hamadah’s 
hypothesis (1970). Beer et al. (1972) have proposed that
the action of drugs capable of reducing anxiety, may be 
mediated by cyclic AMP in the brain. These authors showed 
a significant correlation between the anxiety reducing 
property of the drugs studied (a series of tranquillisers
and antidepressants) and their ability to inhibit rat brain 
phosphodiesterase. Pichard’s results (1972) indicated that 
certain drugs were selective inhibitors of phosphodiesterase 
isoenzymes and that they showed a more marked inhibition 
of the isoenzyme occurring in the tissue in which they 
exerted their pharmacological action. Thus dipyridamole 
(coronary vasodilator) was a more potent inhibitor of 
platlet than brain phosphodiesterase. The reverse situa- . 
tion was true for, the antidepressants, imipramine and 
nortriptyline. Adrenaline and other 3,4 dihydroxyphenyl- 
ethyl compounds were found to be competitive inhibitors , 
of beef heart phosphodiesterase (Goren and Rosen, 1972).
An interesting observation as this type of compound can 
also stimulate cyclic AMP production by activation of 
adenyl cyclase.
Numerous other compounds have been reported as inhib­
itors of phosphodiesterase, eg dihydroergotamine (Ward and 
Fain, 1971; Iwangoff and Enz, 1972), diuretics (Gadd 
et al., 1973), sulphonyl ureas (Goldfine et al., 1971; 
Brooker andFichman, 1971) and papaverine (Kukovetz and 
Poch, 1970; Hanna et al., 1972). Weinryb et al. (1972) 
studied the effect of 158 compounds on rat brain and cat 
heart phosphodiesterase (49 classes of therapeutic drugs) 
and produced a table of the most effective inhibitors.
These were a group of drugs covering a broad spectrum of 
pharmacological actions including dipyridamole (coronary 
vasodilator), pyrvinium panoate (anthelmintic), papaverine 
(cardioactive), diazepam (antianxiety) and anisidone (anti­
coagulant). The antibronchoconstrictor activity of a
triazo-lopyrazine (ICI 58301).and a triazolopyrimidine (ICI 
63197) has also been attributed to their highly active 
phosphodiesterase inhibition (Davies, 1973).
In attempting to assess how the drugs may alter cyclic 
AMP levels the effect of drugs on the adenyl cyclase system 
must also be considered.
Uzunov and Weiss (1971) showed that phenothiazines 
prevented the increase in either rat cerebellar cyclic 
AMP after decapitation or in rat brain slices after nora­
drenaline administration. These effects can be correlated 
with their potency as tranquillisers as can their relative 
inhibition of pineal adenyl cyclase. . Uzunov and Weiss- 
concluded that the primary mode of action is inhibition 
of adenyl cyclase. The mechanism was not entirely clear 
cut, in that phenothiazines may also inhibit phosphodies­
terase and this may be their major function in certain 
regions of the brain, eg the caudate nucleus (Weiss and 
Costa, 1968),
Lithium chloride (25 - lOOmM) inhibited adenyl 
cyclase activity (Dousa and Hechter, 1970) in various 
rabbit tissues. This may account for its therapeutic 
value in the treatment of manics, who were reported to 
have high tissue levels of cyclic AMP. Several reports 
suggested that ethanol (16 - 21g/kg rat) stimulates adenyl 
cyclase (Kuriyama and Israel,. 1973; Green et al., 1970). 
Morphine (acute dosage 15mg/kg) both in vivo and in vitro 
increased brain adenyl cyclase activity in mice, but no 
effect on phosphodiesterase activity was noted (Chou et al. ,
1971). Weinryb et al. (1972) reported that several drugs
stimulate guinea pig lung adenyl cyclase, isoproterenol 
being the most potent, (60% increase in basal activity was 
observed). The other drugs .produced only marginal 
increases in activity, ie 20% or less. Adenosine and 
2 chloroadenosine both increased cyclic AMP concentration 
in platlets, possibly by stimulation of adenyl cyclase 
activity. This was proposed as a mechanism, by which 
these compounds inhibit platlet aggregation (Mills and 
Smith, 1971; . Haslam and Lynham, 1972)..
An alteration of the activity of phosphodiesterase 
and/or adenyl cyclase in vitro may indicate possible 
changes in the intracellular level of cyclic AMP in vivo. 
However, the effect is very difficult to predict. The 
results of the following experiments indicate problems of 
interpretation. The antidepressants imipramine, desipra- 
mine and amitriptyline had been classed as phosphodies­
terase inhibitors; they could, however, produce 5 - 8  fold 
increases in the cyclic AMP level in guinea pig brain 
slices at concentrations that only caused 13% inhibition of
I
the phosphodiesterase. This implies that these compounds 
must stimulate adenyl cyclase (Kodama et al., 1971). 
Chlorpromazine, an inhibitor of both adenyl cyclase and 
phosphodiesterase in vitro, was not found to alter the 
cyclic AMP levels in mouse cerebellum (Ferendelli et al. ,
1972). Huang and Daly (1972) found that both antidepres­
sants (eg imipramine, desipramine and amitriptyline) and 
tranquillisers (chlorpromazine, reserpine) increased cyclic 
AMP levels in guinea pig cerebral cortex and suggested that 
they acted by first enhancing accumulation of extracellular
adenosine which then stimulated cyclic AMP formation 
(Sattin and Rail, 1970). Adenosine stimulation of cyclic 
AMP levels was also proposed as a possible mechanism by 
which chlorpromazine and desipramine increased cyclic AMP 
levels in.rat forebrain (Bernt and Schwabe, 1973). r
The experiments of Dinnerdahl et al. (1973). and
Schonhoffer et al. (1973) add a further dimension to the
action of drugs on the cyclic AMP system. These authors 
found that salicylate and acetylsalicylate both inhibited,.
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the binding of cyclic AMP to', and hence, the activity of a 
protein kinase.in fat cells.. The authors further suggested 
that this may account for the antilipolytic effect of the 
drugs in the fat cell, since the main function of the 
protein kinase affected is the phosphorylation and thus 
iactivation of triglyceride lipase. Aspirin may also have 
an indirect effect on the cellular cyclic AMP level by 
inhibition of prostoglandin synthesis (Vane, 1971) as pros- 
toglandins affect adenyl cyclase to produce their physio­
logical action (Kahn and Lands, 1973).
The cyclic AMP system, as a regulator of many intra­
cellular processes, would be an ideal site of action for 
drugs. To date, no drug has been shown, to exert its .pharma­
cological action exclusively by alterations in intracellular 
levels of cyclic AMP. However, the action of certain 
psychotropic drugs (phenothiazines and tricyclic antidepres­
sants) appears to be intricately involved with this second 
messenger system. In overdose cases this type of drug may, 
therefore, by a direct or an indirect action on the second 
messenger system, produce significant alterations in the 
urinary excretion of cyclic AMP.
SECTION 3 
AIMS AND OBJECTIVES
3. AIMS AND OBJECTIVES
When a drug causes death, so drastic an alteration in­
normal biochemical pathways occurs that a fatal biochem­
ical lesion is produced. One of the main problems with 
suspected drug deaths is the interpretation of the tissue 
drug levels, ie# did-this ■ drug actually cause death?
The aim of this research project is to examine 
whether changes in the level of a single biochemical 
marker can correlate with a fatal dose of drugs.
The urinary level of cyclic AMP was chosen as the 
marker because:-.
(a) The results of several previous investigations 
suggest that urinary cyclic AMP is indicative 
of the activity (stimulation or depression) of 
the central nervous system.
(b) Certain psychotropic drugs have significant 
effects on the cyclic AMP "second messenger 
system" in vitro and thus their action may . 
manifest itself by an alteration in the urinary! 
levels of cyclic AMP.
It was proposed, therefore, to determine whether 
drugs which either stimulate or depress the 'central 
nervous system could significantly increase or decrease 
urinary cyclic AMP levels, when taken in overdose quantity.
Initially, it was essential to determine the stabil­
ity of cyclic AMP in both voided urine and in urine within 
the bladder. After completion of these stability trials 
the contribution of urine flow rate to cyclic AMP excre­
tion was assessed.
The next stage of the study was to establish the 
normal range of cyclic AMP levels likely to be encountered 
in urine samples. The influence of a variety of physio­
logical and dietary factors needed to be investigated.
For example, what is the variation in the 24 hourly cyclic 
AMP level? Is there a circadian excretion pattern?
What is the influence of a changing urine pH, varying 
exercise, varying vitamin C intake or varying alcohol 
intake? The effect of therapeutic doses of drugs on the 
excretion of cyclic AMP must be examined.
For the post mortem studies, it was necessary to 
assay cyclic AMP levels in urine samples from natural 
deaths; do post mortem levels fall within the normal 
range? After assessing post mortem variation in cyclic 
AMP excretion, the cyclic AMP levels in samples from drug 
deaths were measured. Is there a significant difference 
between post mortem cyclic AMP levels from natural deaths, 
as compared#with overdose victims? What is the direction 
of this difference? Is it possible to observe a pattern 
which is indicative of a fatal dose of a particular class
I
of drug?
If successful this study could have two forensic, 
applications
(a) Urines could be rapidly screened to indicate 
whether drugs were involved in the fatality and
(b) as an aid in the interpretation of drug levels.
SECTION 4 
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4. MATERIALS, METHODS AND RESULTS
4.0 Materials 
Phosphodiesterase (Sigma)
Beef heart S ’S* cyclic nucleotide phosphodiesterase 0.39 
units/mg protein (1 unit converts l.Oymol of 3 ’5 ’ cyclic 
AMP to AMP per minute at pH7,5 at 30°C).
Tritiated Cyclic AMP (Radiochemical Centre, Amersham)
|~8-3h ]  Adenosine 3*5’ cyclic phosphate ammonium salt 20,000 - 
30,OOOmCi/mmol was provided in solution (250yCi/005ml). lOOyl 
of this solution was diluted 1:50 with a solution of 1:1 
water:ethanol and was stored in a refrigerator (4°C) in 200yl 
aliquots. An aliquot was diluted (usually 1:30) with pH 7.4 
Tris buffer as required and 50yl of this final dilution was used 
in the assay.
Cyclic AMP (Sigma)
Adenosine 3 ’5 ? phosphoric acid; CjoH^NsOg MW = 347.23.
Master solution made every month (300pmol cyclic AMP/ml 
pH 7.4 Tris buffer) and was stored in a refrigerator (4°C).
i ,
All other chemicals were reagent grade.
Thin Layer Chromatography
Thin layer chromatography was carried out on (100y) 
cellulose sheets (Eastman Chromogram).
Tris Buffer 0.05M (pH7,4)
Hydrochloric Acid IN 50ml
Theophylline Hydrate 1.58g
TRIS 7.18g
2 Mercaptoethanol 500yl
Distilled Water to 1 litre
Charcoal Solution
Norit G S X
Charcoal^/CNorit^Clydesdale Co Ltd) lg
Bovine Serum Albumin 20% 1ml
Buffer (as above) to 10ml
Solution freshly prepared and mixed for 10 minutes 
immediately before use,
Littlefields Medium
Potassium Chloride 186mg
Magnesium Chloride « 47.6mg
Sucrose 8.56g
Tris Buffer (as above) to 100ml
Scintillator
Naphthalene 160g
BBOT 12g
Toluene 1200ml
Methoxyetha.nol . 800ml
TLC Solvent System in in vitro Phosphodiesterase Studies 
n-Butanol ' 45ml
Acetone 15ml
Acetic Acid . 10ml
5% Ammonium Hydroxide 10ml
Water • 20ml
4.1 Inhibition in vitro of Cyclic 3*5' Nucleotide
Phosphodiesterase Activity by Drugs 
For each drug tested, 6 routine mixtures, comprising 
3 tests and 3 controls, were prepared. Each of the test 
mixtures contained cyclic AMP .(0.15}imol), Tris buffer pH
7.5 (8.0pmol), magnesium sulphate (0.4ymol), enzyme (0.01, 
0.005 or 0.0025 units from beef heart) and drug or drug 
salt in a total volume of 200yl. The control mixtures 
were identical but with drugs omitted. The 3 enzyme 
concentrations chosen were those necessary to convert 
approximately 50, 25 and 12% respectively of the cyclic 
AMP present to 5'AMP, after an incubation period of 1 hour 
at 37°C. The reactions were markedly slowed by immersion 
of the tubes in ice. Aliquots (lOyl) were then spotted 
onto Eastman Chromagram cellulose sheets (100y) and devel­
oped in the solvent system (Stahl, 1969) which separated 
the 2 nucleotides (Rf values:cyclic AMP 0.41, 5'AMP 0.25). 
The chromatograms were examined under UV light (254nm) and 
the densities of the 3 test cyclic AMP spots were visually 
compared with those of the controls. A clear visual dif­
ference in densities, between the 2 series of spots, was 
taken as an indication of inhibition. The results are 
given in Table 5. Of the 70 drugs examined, only 8 were 
active at a concentration of 1 x 10_lfM and none of these 
inhibited at 1 x 10“ 5M. At a concentration of 10“2M 7 of 
these 70 drugs caused an alteration in the pH of the 
reaction mixture and, therefore, an apparent inhibition of 
the enzyme. At lower concentrations this pH change was 
less- than 0.2pH units.
From Beof Heart by Drugs
Drug
Minimum Inhibitory* 
Concentration 
(molar)
Trifluoperazine hydrochloride* 
Chlorpromazine hydrochloride 
Triflupromazine hydrochloride 
Picrotoxin
A 9-Tetrahydrocannabinol 
Ergotamine tartrate*
Papaverine hydrochloride* 
L-Ascorbic-acid
1 x 10“ ^
Ph e n e l z i n e .acid sulphate 
Pargyline hydrochloride 
Imipramine hydrochloride 
Nortriptyline hydrochloride 
Amitriptyline hydrochloride - 
Desipramine hydrochloride 
Methaqualone hydrochloride* 
Serotonin creatinine sulphate 
Theophylline
Pentazocine hydrochloride 
Lysergide acid tartrate 
Ibogaine hydrochloride 
Nalorphine hydrobromide 
Salicylic acid 
Phenylbutazone* 
Dextromethorphan hydrobromide
V '
• * ' ^
1 x 10“ 3
Chlordiazepoxide*T
Caffeine
Codeine phosphate .
Methadone hydrochloride
Ethoheptazi.ne citratet
Paracetamol
Acetylsalicvlie acidt
Mescaline hydrochloride 1 x 10-2
A 8-Tetrahydrocannabinol*
Mepyramine maleatet -
Promethazine hydrochloride*
Histamine dihydrochloridet
Tetracycline hydrochloride*t
Strychnine hydrochloridef
Reserpine* '
* Not soluble.at that concentration
f pH of the reaction mixture altered by the drug 
Ref Moffat et al,, 1972
Table 5 Cont'd
Drug
Minimum Inhibitory* 
Concentration 
(molar)
Diazepam*
Nitrazepam*
Oxazepam* .
Meprobamate
Haloperidol*
Glutethimide
Carbromal* ' 
Chloral hydrate 
Ethyl alcohol 
Adrenaline*
Amphetamine sulphate 
Methylamphetamine hydrochloride 
Ephe'drine hy.drochloride • 
Fenfluramine hydrochloride 
Isoprenaline hydrochloride 
Diethylpropion hydrochloride 
•Phenmetrazine hydrochloride 
Nikethamide
Diamorphine hydrochloride 
Morphine sulphate 
Pethidine hydrochloride 
Propoxyphene hydrochloride* 
Cocaine hydrochloride 
Atropine sulphate 
Benzocaine*
Lignocaine hydrochloride 
Diphenhydramine hydrochloride 
Antazoline hydrochloride 
Methyldopa
Pyridoxine hydrochloride 
Nicotinamide
No activity at 
1 x 10“ 2
* Not soluble at that concentration
4.2 The Measurement of Creatinine
The determination of creatinine in urine was carried 
out in the autoanalyser by a Technicon modification of the 
procedure of Folin and V/u in which red creatinine picrate 
‘is formed (Hawk et al., 1947). The flow chart is shown 
in Figure 4. '
The urine sample was automatically diluted 1:600 and 
segmented with air. The sample stream then joined a 
stream formed by the combination of picric acid (0.04M) and 
sodium hydroxide (0.5M). The streams were sent through a 
time delay coil (to stabilise the temperature of the reac­
tion) and then into a colorimeter. The developed colour 
was read at 505nm. A range of creatinine standards (in 
0.1M HC1) from 0.1 to 2.0mg/ml was used to construct a 
standard curve. The system is capable of handling 40 
samples per hour and the intra-assay coefficient of varia­
tion was ±1%.
In a previous study Owen et al. (1954) using a bacterium 
(Corvnebacterium iireaf aciens) and an absorbent (hydrated 
aluminium silicate), which respectively destroys or absorbs 
creatinine, found that non creatinine chromagen in diluted 
urines constituted 5% of the total chromagen. The above 
authors also stated that creatinine was completely recovered 
from urine samples.. Therefore, in this study no correction 
was made for non creatinine chromagen.
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4.3 The Measurement of Urinary Cyclic 3*5' Adenosine
Monophosphate
A sensitive saturation assay was used to measure
urinary cyclic AMP. The method is based on a bovine ■
adrenal binding protein which has a high specificity for
cyclic AMP (Brown et al. , 1971). / •
Bovine adrenals were collected and transported in
ice to a refrigerator at 4°C. After stripping off and
discarding the medulla the cortices were chopped and homo-
\ \
genised in ice cold Littlefields medium. The homogenate 
was initially spun at 2000g for 5 minutes and the super­
natant was respun at 5000g for 15 minutes. The resultant 
supernatant was stored in 0.5ml aliquots at -20°C (no 
appreciable loss in binding capacity could be detected for 
up to 3 months). An aliquot was thawed and diluted with 
'50mM Tris HC1 buffer pH 7.4 as required.
In this assay maximum sensitivity is obtained by 
binding 25% of the tritiated cyclic AMP in the incubation"; 
tube (a percentage derived from the theoretical concepts 
of Ekins and Newman,. 1968) which involves an approximate 
1:50 fold dilution of the binding protein. Each assay 
tube contained 50pl of a known amount (0 **- 3. 6pmol) of 
cyclic AMP standard, or of an unknown sample; 50yl of 
tritiated cyclic AMP (approximately lpmol); lOOyl of the 
appropriate dilution of binding protein and buffer, to a 
final volume of 300yl. Urine samples were usually dilu­
ted 1:25 to 1:200. (The creatinine concentration of the 
urine sample was estimated first as it indicated the • 
degree of dilution necessary to bring the cyclic AMP
within-the range of the standard curve.) Incubation 
tubes were left at room temperature for 1.5 hours and then 
lOOyl of a suspension of charcoal were added to each tube. 
The tubes were briefly agitated (vortex mixer) then centri­
fuged (28.000g) for 3 minutes. After centrifugation lOOyl 
of supernatant (ie bound fraction) were pipet.ted. into 8ml 
of the scintillation medium. Calibration curves were 
plotted of the percentage bound tritiated cyclic AMP against 
the amount of nucleotide (pmol) per standard tube. The 
amount of cyclic AMP in the unknown sample could be deter­
mined from these curves (Figure 5). ' All samples were 
assayed in triplicate.
The correction for background count rate was found by - 
running blanks, containing everything apart from the binding 
protein in each assay. In order to construct the standard 
'curve it was also essential to run "100% tubes" to which 
lOOyl of buffer instead of charcoal were added. These also 
enabled one to check the correct functioning of the binding 
protein and the activity of the tracer.
Sensitivity and Specificity of the Assay
The lower limit of detection of’ cyclic AMP was 0.7pmol 
per incubation tube. The response curves for other cyclic 
nucleotides are shown in Figure 6. Adenosine, AMP, ADP,
ATP, 5'GMP,. thymidine 3 ’5' cyclic monophosphate and adeno­
sine 2 ’3* cyclic monophosphate did not appear to cross 
react in the system at concentrations of up to 30nmol per 
incubation tube (Brown et al., 1971). Cyclic GMP is the 
only other naturally occurring cyclic nucleotide found in 
urine and its concentration is about one third that of
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cyclic AMP (Price et al. , 1967). Interference is, there­
fore, not an important factor as cross reaction figures 
(Figure 6) indicate that the binding protein is approxi­
mately 50 times more sensitive to cyclic AMP than cyclic 
GMP. •
4.4 Modification of the Binding Assay ' •;
The original assay procedure of Brown et al. (1971)
was modified slightly and now involves incubation at room 
temperature instead of 4°C. . This was purely for conveni-
ence as it dispensed with the necessity of working in a 
cold room. At room temperature the carbon contact time 
was found to be one of the most critical factors (ie,the 
time that the charcoal suspension is in contact with the 
incubation medium before centrifugation). An assay was, 
therefore, carried out at room temperature in which the 
contact.time was varied from a minimum time (which involved 
10 seconds of contact between the charcoal and the incuba­
tion medium) before centrifugation up to 16 minutes of 
contact.
The results (Figure 7) indicate that if the minimum 
contact time is classified as 100% binding, then a one
minute contact time gives 84% and 16 minutes gives 10%
binding. The loss of cyclic AMI5 from the binding protein
can be explained by consideration of the following equili­
brium
Binding Protein . Kj Solution free K 3 Charcoal
___-A ._____
(bound cyclic AMP) ' K 2 cyclic AMP k J~ (bound
cyclic AMP)
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The charcoal disrupts the K i/K2 equilibrium by rapidly 
removing all free cyclic AMP from solution and hence 
causes a continuous release of cyclic AMP from the binding 
protein. Therefore, in order to increase the reproduci­
bility of the assay a consistent carbon contact time must 
be adopted. A contact time of 90 seconds-, at room temper­
ature, was used as this allowed a reasonable time in which 
to add charcoal to a batch of 12 tubes (capacity of the 
microcentrifuge). Intra assay reproducibility was ±4.8%
(30 measurements) and inter assay was ±10% (sample reassayed 
eight times each time in triplicate, see Appendix .la).
The format of the standard curve was also changed.*
The original curve (Figure 5) was based on the percentage 
of tritiated cyclic AMP in the incubation medium that was 
bound, plotted against the quantity of unlabelled cyclic 
AMP added to the incubation tube. However, by plotting 
the ratio of the total amount of tritiated cyclic AMP to the 
amount of bound tritiated cyclic AMP against the quantity 
of unlabelled cyclic AMP added.to the incubation tube, 
linearisation of the plot was obtained (Figure.8). The 
method of least squares (Appendix lb) enabled the best 
straight line to be drawn and a simple equation was derived 
for the line. The method prevented the possible construc­
tion error in drawing a curve and improved the reproduci­
bility of. the assay.
From theoretical considerations (Midgley, 1969) one 
would expect that the standard curve (Figure 8) could devi­
ate slightly from linearity at very low concentrations of 
cyclic AMP, ie below Ipmol per incubation tube. A complete
* Based on theoretical data of Midgley, et al. (1969)
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linearisation of the standard curve can be achieved by
using logit plots. The logit of a response Y, ie log 
Y
-*-s plotted. against the log of the nucleotide concen- • 
tration (Kirkham and Hunter, 1971).
Bwhere Y = ^  and B = Fraction of tracer attached to
binding protein.
Bo = Fraction of tracer attached to
binding protein in the absence 
of unlabelled nucleotide.
and F = Fraction of tracer not attached
to the binding protein.
Fo = Fraction of tracer not attached
to the binding protein in the
absence of unlabelled 
nucleotide.
However, a logit plot was not required in this study as
the loss in linearity occurred in a region of the standard
curve (Figure 8) which was not used (Appendix lb).
4.5 The Effect of Drugs on the Cyclic AMP and Creatinine 
Assays
h _
It is feasible that drugs, or their metabolites, may 
affect the cyclic AMP assay. They may either attach 
themselves to the binding protein, causing a conforma­
tional change, or through steric hindrance affect the 
cyclic AMP binding site. In the case of compounds with a 
similar structure to cyclic AMP, eg the methyl xanthines, 
there may be competition for the binding site (Figure 9).
B/For Y = -----°r Bo/Fo
Figure 9 Drug Interference With The Cyclic AMP Assay
D
(4) 1 ' a )
BP - D 5== D + ‘ BP + cAMP* BP - cAMP*
(3) +
cAMP (2)
%
BP - cAMP
cAMP - cyclic AMP; cAMP*.- tritiated cAMP;
BP - binding protein; D - drug.
(1) Equilibrium between BP and tritiated cyclic AMP.
(2) Unlabelled cyclic AMP acting as competitive inhibitor 
of tritiated cAMP binding of BP.
(3) Drug acts as competitive inhibitor of tritiated cAMP 
binding of BP.
(4) Drug alters conformation of BP to affect binding of 
tritiated cyclic AMP or sterically hinders tritiated 
cyclic AMP binding.
The urinary concentrations of a collection of drugs 
and .metabolites occurring in overdose cases were estimated 
as shown in Table 6 (Clarke, 1969; Sunshine, 1969). The 
drugs were dissolved in assay buffer (with, if necessary, 
several drops of alcohol) to the stipulated concentrations. 
50yl of the drug solution were added to the -assay instead 
of 50yl of buffer. Urines were normally diluted 1:25 to 
1:200, however., ,the drug solutions were added undiluted to 
produce a maximum effect.
The drug solutions were also diluted to the previously 
tabulated concentrations with urine and were compared with 
a control urine (the same urine with no drug added) to se,e 
if the creatinine assay was affected.
The drugs gave false positives in terms of cyclic AMP 
in the binding assay from 0.-»• 0 .02nmol/ml of starting solu­
tion. The assay of creatinine was not noticeably affected 
by the drugs at the concentrations stipulated.
4.6 The Stability of Urine Samples •
A sample of urine w a s .divided into 3 vials which were
stored in the deep freeze (approximately -20°C), refrigera-
*
tor (approximately 4°C) and at room temperature (approxi­
mately 20°C). The cyclic AMP concentration.in the urine 
sample was then periodically redetermined. Examining 
Table 7a the room temperature sample, showed a marked 
decrease in cyclic AMP content between 1 week (88%)* and 1 
month (55%) after sampling. The sample stored in the 
refrigerator -maintained its cyclic AMP concentration for 
at least a month showing a greatly reduced level after 3
* Figures in parenthesis indicate the percentage of cyclic 
AMP remaining.
Table 6
Drug Interference in the Protein Binding Assay
for Cyclic AMP
Drug
Expected Drug 
Concentration 
in Urine 
in Overdosage 
yg/ml
False 
Cyclic AMP 
Concentration 
nmols/ml
Amitriptyline 500 0
Amylobarbitone 20 0.01
Ascorbic acid 1000 0.005
Aspirin 100 0.005
Carbromal* 1000 0.01
Caffeine 200 0.01
Chlorpromazine 20 0.01
Desipramine 20 0.01
3 Hydroxyamylobarbitone 20 0.005
Oxyphenbutazone 400 0.02
Methaqualone 20 0.005
Paracetamol 2000 0.005
Pentobarbitone 700 0.005
Phenobarbitone 400 0 . 005
Phenylbutazone 100 0.01
Quinine 1000 0.005
Salicylic acid* 2000 0
Sulphafurazolef 150 0.005
* A few drops of alcohol were -used to dissolve the drugs 
to the stipulated concentrations.
t Maximum- solubility used.
months (9.5%). In contrast, the cyclic AMP level in the 
sample stored in the deep freeze was preserved for at 
least 3 months. However, after 7 months, the deep frozen’ 
sample showed a reduced cyclic AMP level (74%) indicating 
that deterioration does eventually occur in the deep 
freeze.
In further studies (Table 7b) urine samples were 
obtained from 5 volunteers. The cyclic AMP was immedi­
ately assayed and then reassayed after the urine samples 
had been left at room temperature for.3 days.
Results in Table 7b show that (considering interassay 
coefficient of variation of ±11%) there was no noticeable 
decrease in cyclic AMP level for any of the volunteers 
after 3 days.
4.7 The Stability of Cyclic AMP in the Bladder
Fifteen human bladders removed at the post mortem 
examination were investigated, but only 3 were found suit­
able for the study. The other 12 bladders either con­
tained no urine (emptying of the bladder appears to be a 
common occurrence at death) or such small volumes that 
only 1 or 2 samplings were possible.
After removal of the bladders, samples of urine were 
immediately withdrawn (l-2ml). The 3 bladders were stored 
in a refrigerator and urine samples were withdrawn as shown 
in Table 8 . (The bladders were stored in a refrigerator 
to simulate the storage of a body in a mortuary.)
Accepting an interassay coefficient of variation of 
±11% there was little apparent change in the cyclic AMP
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Table 7b
The Stability of Cyclic AMP in Urine Samples
Stored at Room Temperature
\t
Subject
Initial 
Cyclic AMP 
Level 
nmol/ml
Cyclic AMP 
Level After 
3 Days. 
nmol/ml
I 3.0 3.2
II 2/9 2.5
III • 3.8 3.4
IV 1.5 1.6
V 3.2 3.0
Murad (1973) stated that cyclic AMP was stable in 
unacidified urine samples stored at room temperature 
for 2 to 3 days.
level of bladder one after 2 days and bladders two and 
three after 4 and 3 days respectively (Table 8 ).
.4.8 The Preservation of Cyclic AMP at Room Temperature
As urine samples, from drug overdose cases, would
have to be sent through the post it was necessary to find
a preservative, for urinary cyclic AMP, that.was suitable
for use at room temperature. The organic mercurials,
phenyl mercuric nitrate and thiomerselate; the antibac-
terials, sodium azi.de and sodium fluoride; the phosphodi-
\
esterase inhibitors, theophylline and chlorprornazine were 
selected (Table 9). A urine sample was divided into 
eight 10ml portions and to seven of these portions the 
relevant preservative was added. The urine samples were 
stored at room temperature and the cyclic AMP concentra­
tions were redetermined periodically.
From Table 9 the cyclic AMP in the control urine, 
ip,no preservative, dropped to a very low level after 7 
days.
In the' amounts stated, phenyl mercuric nitrate with 
and without fluoride; sodium fluoride; sodium azide and 
chlorprornazine were all satisfactory in that the level of 
cyclic AMP did not show a marked decrease after 3 weeks of 
storage at room temperature.
The preservative chosen was the phenyl mercuric 
nitrate and sodium fluoride tablet. The tablets.will 
also preserve the creatinine concentration of a urine 
sample, stored at room temperature for at least 3 months. 
Whereas creatinine in a control urine, ie no preservative, 
had partially disappeared after 1 month and completely 
after 3 months (Table 10).
Table 8
Stability of Cyclic AMP 
in the Bladder at 4°C
Days After Concentration of Cyclic AMP nmols/ml
Autopsy Bladder 1 Bladder 2 Bladder 3
0* 0.38 0. 35 0.85
1 0. 33 0. 32 0.84
2 0.32 0. 75
3 0 . 81
4 0.35
* Urine sample obtained at autopsy.
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Table 10
vStability of Creatinine (mg/ml) at Room Temperature
With and Without 
Phenyl Mercuric Nitrate and Sodium Fluoride
Sample
Time (days)
0 27 56 82
Untreated
Urine
1.42 1.1 0.17 —
Urine 
+50rng PMN 
+ 100rng NaF 
(Tablet)
1.42 1.36 1.37 1.23
The experiments 4.9-4.16 concerned with factors 
affecting urinary cyclic AMP in vivo were carried 
out on normal healthy volunteers. Alcohol was not 
consumed during the period of study unless otherwise 
stated; tea and coffee intake was noted.
4.9 The Effect of Change of Urine Flow Rate on Cyclic AMP 
Excretion
This section was separated into two sets of experi­
ments :
(a)- The initial set of experiments consisted of 
collecting the hourly urine samples plus an 8 
hour overnight sample, over several days from 
two subjects.
(b) The second set of experiments, dealing with urine 
volume, consisted of collecting 24 hourly urine 
samples for a normal then a water loaded condi­
tion from five subjects.
When the urine flow rates for the 2 individuals 
were plotted against cyclic AMP excretion rates (Figure 
10) no significant correlation (10% level) between the 
2 rates was observed (Appendix 'lc), even though there 
was an extreme variation in urine flow rate, ie 0.15 - 
8.4ml/rnin.
After water loading, which increased urine output in 
all cases, 3 subjects showed a decrease and 2 showed 
an increase in 24 hourly cyclic AMP excretion (Table 11). 
Since the coefficients of variation in the 24 hourly cyclic 
AMP excretion (section 4.11) over several weeks were found 
to be 14% and 7% for subjects I and II respectively, it 
appears that the subjects were only showing a normal vari­
ation..
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Table 11 ~
24 Hourly Cyclic AMP Excretion and Urine Volume
Subject
Normal Water- Loaded*
Cyclic AMP 
(ymols)
Urine
Volume
(ml)
Cyclic AMP 
(ymols)
Urine
Volume
(ml)
ACM (I) 3.0 1220 2.6 3360
DAP 4.0 820 5.2 1170
ERR 2.7 . 1575 2.9 4100
PO (II) 4.5 1245 3.8 3120
TSH 5.6 1805 5.2 4420
* Volunteers were asked to drink as much water as 
possible and generally the volume imbibed exceeded 
three litres.
(a) Urine samples from 1.00 male ancl 55 female sub­
jects were analysed for cyclic AMP and creatin­
ine, and the ratio (nmol/mg) calculated (Tables 
12fand 131) . The mean ratios (nmol cyclic AMP/ 
mg of creatinine) were 2.9 (SD 0.78, coefficient 
of variation 27%) for male subjects and 4.3
(SD 1.1, coefficient of variation 25%) for
females. These ratios.are less variable than
s
the cyclic AMP concentrations (nmol/ml) which 
have a mean, for male, of 3.4 (SD 2.1, coeffi­
cient of variation 62.6%) and for female of 4 .3 -
(SD 2.7, coefficient of variation 63.6%).
The normal ranges of the cyclic A.MP to cre­
atinine ratios were set at the 95% confidence 
level (ie ±2 standard deviations) which would 
produce ranges for the male and female subjects 
respectively of 1.3 - 4.5nmol/mg and 2.1 - 6.6 
nmol/mg. The mean cyclic AMP to creatinine 
ratios for the male and female subjects were 
significantly different at the 0 .1% level*.
(b) The cyclic AMP to creatinine ratios were also 
derived for 9 children (Table 14). The mean 
ratio was 6 .Onmol/mg (coefficient of variation 
45%) for the males (5) and 6 .lnmol/mg (coeffi­
cient of variation 24%) for the females (4).
Both these mean ratio values show marked 
increases over the mean value of the adult 
population. •
Students t test used for comparison of means.
In Appendix 2a and 2b
Table 14
The Cyclic AMP/Creatinine Ratio in Children
No. Cyclic AMP nmols/ml
Creatinine
mg/ml
Cyclic AMP 
Creatinine 
nmols/mg
Age
Years Sex
1 4.8 0.46 10.4 2 M
2 0 . 18 0.04; 4.6 2i F
3 5.6 0.93 • 6.0 3 M
4 2.8 0.38 7.3 ■4i. F
• 5 9.4 2.0 4.7 5-2 M
6 8.2 1.6 5.1 6 F
7 3.3 0.45 7.4 7 F
8 6.5 1.12 5.8 8 M ■
9 1.5 0.46 3.2 .Hi M
M '= Male; F = Female.
(a) The measurement of the cyclic AMP level (ymols) 
in 24 hourly urine samples in order to determine 
the daily variation in level for two subjects.
(b) Eight hourly urine samples were collected for 7 
days (non-consecutive) from both subjects. The 
cyclic AMP levels were measured to determine 
whether a circadian cyclic AMP excretion pattern ' 
existed.
(c) Hourly urine samples (14 and 16) were collected 
from both subjects and analysed for cyclic AMP 
content.
For subject I the mean daily excretion was 3.9v»mols 
(coefficient of variation 14%) for fourteen 24 hourly 
samples analysed. The mean of.fifteen 24 hourly samples
i
for subject II was 4.1ymols (coefficient of variation 
6.7%). Both the coefficients of variation were derived 
using the best estimate of a standard deviation of a popu­
lation from a small sample (i\ppendix la). From Table 15 
and Figures 11a and 11b it can be seen that approximately 
20% less cyclic AMP is excreted during the nocturnal period 
than the two other periods of the day (significant at the 
5% level*). There was no significant (5% level*) differ-, 
ence in the amount of cyclic AMP excreted during the 0800 - 
1600 and 1600 - 2400 periods of the day.
* Students t test used to compare means.
Table 15
Excretion of Cyclic AMP During 8 Hour Periods 
(Subjects I and II)
Day
Cyclic AMP (ymols)
0800 - 1600 
hrs.
1600 - 2400 
hrs.
2400 - 0800 
hrs.
I II I II I II
. 1 1.43 1.53 1.12 1.43 0.93 • 1.16
2 1.14 1.65 1. 17 1.39 1.00 1.26
3 1.21 1.52 1. 33 1.43 0.97 1.31
4 1.44 1.67 1.49 1. 52 1.05 1.20
5 1. 37 1.58 1.41 1.53 • 1.00 1 . 18
6 1.07 1. 34 0.95 1. 73 0.94 1.22
7 1. 19 1.46 1.42 • 1.69 0.98 1. 37
Mean 1.26 1.54 1.25 1.53 0. 99 1 .'24
Coefficient 
of Variation 11.8% 7.4% 16.4% 8.7% 4.5% 6 .0%
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The hourly cyclic AMP to creatinine ratio for subject 
I varied between 2.2 and 2.8nmols/mg and for subject II
2.6 to 3.8nmols/mg (Figures 12a and 12b). The mean cyclic 
AMP to creatinine ratios were also determined for a collec­
tion of urine samples where no special factors were under 
test (the urine samples involved 1 hour, 8 hour and 24 
hourly collection periods). For the 42 samples analysed 
from subject I the mean cyclic AMP to creatinine ratio was 
2.5nmols/mg (coefficient of variation 14.5%) and for sub­
ject II the mean cyclic AMP to creatinine ratio was 2.7 
nmols/mg (coefficient of variation 17.6%) for the 67 
samples analysed. ■ _ .
4.12 pH .and Cyclic AMP Excretion
The pH trial was concerned with producing a urine of 
alkaline pH to see if this affected the excretion of cyclic 
AMP, which is a phosphate ester of pKa 3.82. A total of 
14g of sodium bicarbonate in 2g quantities (every 2 hours 
from 0900 onwards) were administered to both subjects I 
and II. The pH of each urine sample was checked. 
Twenty-four hourly urine samples were collected and the 
cyclic AMP levels were determined.
The pH values of subject I and subject IITs 24 hourly 
urine samples were 8.04 and 7.61 respectively. Subject I 
excreted .3. 26ymols (normal 3.9 ±1.lymols/24 hours) and 
subject II excreted 4.09ymols (normal 4.1 ±0.6ymols/24 
hours) of cyclic AMP during the experiment.
4.13 Exercise
The effects of gardening, swimming and football on the 
24 hourly cyclic AMP level (ymols) were studied. The 24 
hourly urine samples were collected and analysed for cyclic
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AMP on the exercise days. The effects of exercise on the 
8 hourly cyclic AMP to creatinine ratios of subject I were 
also determined. The cyclic AMP excretion of subject I 
expressed as nmols/mg of creatinine and ymols/24 hours was 
not significantly (ie outside the subject’s normal range)f*'
affected by either football, swimming or gardening.
Similar results were obtained for subject II (Table 16).
4.14 Alcohol and Cyclic AMP Excretion
The initial experiments were concerned with the effect 
of different quantities of alcohol on the 24 hourly excre­
tion level of cyclic AMP. The 24 hourly excretion level 
of cyclic AMP was measured after the consumption of 1, 2 
or 3 pints of beer (in one case a single whisky was inclu­
ded) see Table 17. One pint of beer or 1 double whisky 
contains approximately 15g of ethanol (Walls and Brownlie, 
1970). In the second aicohol trial the effect of alcohol 
on the hourly excretion of cyclic AMP by subject II was 
evaluated. Subject II consumed 15, 30, 60 and 90g of 
alcohol on separate days. Absolute alcohol was diluted 
with distilled water and consumed at 1100 hours as quickly 
as possible. * •
Results (Table 17) indicate that 1 of the four 24 
hourly urine samples from subject I and 5 of the eight 24 
hourly urines from subject II gave a. cyclic AMP excretion . 
in excess of 2 standard deviations from the mean level.
No dose relationship was observed. Figure 13 shows that 
after consumption of 15, 60 and 90g of alcohol the hourly 
cyclic AMP to creatinine ratios for subject II do not 
exceed his normal range (1.8 - 3.6nmols/mg). However,
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after consumption of 30g of alcohol 2 of the hourly ratios 
just exceeded this normal range.. None of the 24 hourly 
cyclic AMP to creatinine ratios exceeded the normal ratio • 
range for either subject.
4.15 Vitamin C and Cyclic AMP Excretion
One gram of ascorbic acid was administered to subject 
I twice daily (0900 and 2100 hours) for 4 days, and the 24 
hourly cyclic AMP levels were determined. One gram of 
ascorbic acid was administered to subject II at 0900 hours 
on 4 consecutive days. Four hourly urine samples were 
collected as well as the 24 hourly sample. The cyclic 
AMP level (pmols/24 hours) and creatinine ratios (nmols/mg) 
were determined for all urine samples (Table 18).
Two grams of ascorbic acid did not significantly 
alter the mean 24 hourly excretion of cyclic AMP or cyclic 
AMP to creatinine ratio for subject I. (not significant at 
the 5% level*). However, lg ascorbic acid did signifi­
cantly increase the mean 24 hourly excretion of subject II 
(5%* level). The mean of the 4 hourly cyclic AMP to 
creatinine ratios for subject II was also significantly 
higher than the normal mean ratio figure (5%* level) for 
subject II.
4.16 Therapeutic Doses of Drugs and Cyclic AMP Excretion 
(a) Caffeine
The 24 hourly level of cyclic AMP was determined 
for subject II on 2 separate days during which 
he consumed 10 cups of coffee or 10 cups of tea.
* Student t test used to compare means.
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(k) Amphetamine
Amphetamine sulphate was administered orally as 
a 20mg dose to both subjects and subsequently 2 
hourly urine samples were collected and assayed 
for cyclic AMP. The complete 24 hourly urine 
sample was collected.
(c) Amylobarbitone
The above experiment was- repeated with an oral 
dose of 200mg of sodium amylobarbitone.•
(d) Imipramine
The above experiment was repeated with two 25mg 
tablets of imipramine hydrochloride administered 
to subject II at 0900 and 1600 hours.
(e) Trifluoperazine
On the first day two 2mg doses of trifluopera­
zine hydrochloride were administered orally to 
subject II at 0900 and 1600 hours respectively. 
On the second day (non-consecutive) a lOmg dose 
of trifluoperazine hydrochloride was adminis­
tered to subject II at 0900 hours. UrineN 
; •
samples were collected as above.
There was a gap of at least a week between each drug 
trial.
Subject II excreted 4.1 and 3.9.ymols of cyclic AMP/
24 hours after imbibing coffee and tea respectively.
Both results are within 1 standard deviation of the mean 
24 hourly excretion level of subject II. The 24 hourly 
excretion of cyclic AMP and 2 hourly cyclic AMP to creat­
inine ratios of subject I did not exceed their normal rang
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after amphetamine and amylobarbitone administration. The 
same results were obtained for subject II after imipramine 
and amylobarbitone administration. However, after both 
amphetamine and trifluoperazine administration the 24 
hourly excretion level of cyclic AMP and some 'of the
cyclic AMP to creatinine ratios fell outside the normal
range (Table 19; Figures 14, 15 and 16).
4.17 Factors Which may Affect Post Mortem Urines 
(a) The presence of blood
A 60ml samples of urine from subject II was divi- 
■* ded into three 20ml samples to which no blood,
5pl and 50yl of fresh blood were injected respec­
tively. The urines were analysed before the 
addition of blood; then at 1 hour, 1 day, 2 days,
1 week and 1 month periods. The samples of 
urine were placed in a deep freeze 1 hour after 
the addition of blood and immediately replaced in 
the deep freeze after each subsequent analyses.
Within the error of the assay, neither of the 
urine samples showed a decrease in cyclic AMP con­
tent for at least 1 month after the addition of 
blood (Table 20). Subsequently 4 more urine 
samples (20ml), ie subjects II, III, IV and V,were 
assayed for cyclic AMP content before the addition 
of blood and also after the addition of blood, 1 
hours incubation at room temperature and 1 months 
storage in the deep freeze. None of the urines 
showed a decrease in cyclic AMP content (Table 20).
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The Inhibition of Phosphodiesterase by addition
of a Phenyl Mercuric Nitrate and Sodium 
Fluoride Tablet 
Phosphodiesterase from bovine heart (Sigma) was 
used for the study. A tablet, containing phenyl 
mercuric nitrate (50mg) and sodium fluoride 
(lOOmg), was dissolved in iOOml of buffer (Tris 
pH 7.5 containing 2mM magnesium sulphate) to 
produce a solution which contained a.concentra­
tion of inhibitor similar to that of a urine
i
sample. :
The assay tubes were prepared as stipulated in 
Table 21. The cyclic AMP solution added con­
tained O.lSymols in 50yl. The phosphodi­
esterase solution contained 0.01 units per 50yl 
(unit as defined in materials and methods, p44 ). 
All the solutions were prepared in the pH 7.5 
tris buffer. The tubes were incubated at 37°C 
for 1 hour and the reaction was terminated by 
immersing the tubes in a boiling water bath for 
5 minutes. 50yl of the final solution (ie 
200yl) were diluted 1 :10  ^ and assayed for cyclic 
AMP. The phenyl mercuric nitrate sodium fluo­
ride solution produced a false increase in cyclic 
AMP level of the final solution equivalent to 
O.lnmols/ml under the conditions of dilution. 
Tubes 2, 3 and 4 showed that 60% of the cyclic 
AMP wa s •hydrolysed by the enzyme and, that after 
subtracting the inhibitor interference effect,
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only 16% of the cyclic AMP was hydrolysed in
the presence of inhibitor, ie 73% inhibition of
the enzyme occurred.
18 The Cyclic AMP to Creatinine Ratio in Post Mortem 
Urine Samples 
. (a) Natural deaths
• ‘ Initially the cyclic AMP to creatinine ratio was
determined in 26 post mortem urines from subjects 
whose deaths were attributed to natural causes'. 
The urine samples were withdrawn from the blad­
ders during the autopsies and immediately stored 
in the deep freeze but no inhibitor was added. 
Fifteen’of the samples had reproducible ratio 
values (Table 22), but the remaining samples 
showed a marked fall in cyclic AMP content on 
repeated analyses and therefore were rejected.
Of the 15.samples showing reproducible results,
11 were within the normal range for men and’ 
women. Sample 14a (1.lnmols/mg) was just below 
the lower end of the normal range for men (ie 
1 .3nmols/mg) and sample 8a (0 .8nmols/mg) was 
well below the lower end of the male range.
For females samples no. 2a and 7a were just 
, below and distinctly above the lower and upper 
ends respectively of the normal range (ie 2.1 - 
6 .6nmols/mg).
Table 22
The Post Mortem Urinary Cyclic AMP/ 
Creatinine Ratio
Siample
Number
Cyclic AMP 
Concentration 
nmols/mg
Creatinine 
mg/ml
Cyclic AMP 
Creatinine 
nmols/mg
Sex
la • 3.7 1.4 2.6 M
2a * 0 .8 / O '. 5 1.5 F
3a 3.8 0.93
r
4.1 M
4a 1.9 0.78 2.4 M
5a 4.6 0.98 4.7 F
6a 0.4 0.1 4.0 M
7a 3.3 0.41 8.1 F
8a 0.5 0.63 0.8 M
9a 0.8 0.37 2.1 M
10a 0.7 0.53 1.3 M
11a 2.0 0.73 2.7 F
12a 4.5 0.86 5.3 F '
13a 1.2 0.93 1.3 M
14a 0.7 0.65 1.1 M
15a 4.1 0.91 4.5 M
M = Male; F = Female
Post mortem urine samples from "natural causes"
deaths to which an inhibitor tablet (50mg 
phenyl mercuric nitrate, lOOmg sodium 
fluoride) had been added 
Forty urine samples, from subjects whose deaths 
were attributed to natural (ie non-drug) causes, 
were collected and had inhibitor tablets added 
immediately after sampling. The samples were 
stored in a deep freeze before analyses. On 
repeated analyses, none of the samples showed a 
decreasing cyclic AMP level. Twenty out of 
40 samples (Table 23) had cyclic AMP to creatin­
ine ratios outside the normal range for men and 
women. The deaths were also classified by the 
pathologist as Fast (a sudden death, ie within 
approximately 2 hours) and Slow (a lingering 
death, ie usually longer than 24 hours) designa­
ted ”F" and "S" respectively. .
Post mortem urine samples from drug deaths 
Fifty-five urine samples were collected from drug 
deaths. Inhibitor tablets were added to the 
urine samples either by the pathologist (at the 
autopsy) or on arrival at the forensic science 
laboratory. The time period between the person 
being last seen alive and the discovery of the 
body was noted. Twenty-four samples had cyclic 
AMP to creatinine ratios that were outside the 
normal range for men and women (Table 24).
"Natural Death" Urines and the
Cyclic AMP/Creatinine Ratio 
(Male)
Reference . 
Number
Age ' 
Years
Cyclic AMI5 
Creatinine 
Ratio 
nmols/mg
Fast / 
Slow 
Death
Cause of Death
lb 3 9.6 ‘ F • Subarachnoid Haemorrhage, j Cardiomegaly
2b 75 6.3 S Bronchopneumonia, Chronic j Bronchitis, Emphysema j
3b 20 5.7 Semi / Fast
Head Injury & Subdural ! 
Haemorrhage, Glandular 
Fever
4b 18 5.4 F
Cerebral Laceration, 
Comminuted Fracture of the 
Skull consistent with RTA
5b 73 4.7 F
l
Calcified Non Rheumatic 
Aortic Valve Disease
6b 66 4.4 s Chronic Interstitial Pneumonitis
7b 69 4.4 F
Coronary Occlusion, 
Coronary Atherosclerosis
8b 69 3.5 S
Shock, Mesenteric Artery 
Thrombosis, Atheromatous 
dissecting Aneurysm of 
Aorta
9b 60 3.3 F
Coronary Occlusion,
- Coronary Atherosclerosis
10b 60 3.1 F Myocardial Infarction
lib 60 2.9
■f
S
Cardiac Failure, Rheumatic 
Aortic Stenosis
• 12b 76 2.7 S
Carcinomatosis, Carcinoma 
of Stomach
13b 63 2.6 ?
Alcoholic Degeneration of 
Liver and Heart
14b 81 2.5 F
Bronchopneumonia, Fatty 
Disease of Liver
15b 96 2.4 S
Bronchopneumonia, Patholog­
ical Fracture of Hip,Osteo­
porosis of Hip, Myocardial 
Ischaemic Fibrosis
16b 77 2.2 F
Myocardial Infarction, 
Coronary Atherosclerosis, 
Heart & Kidney Disease
18b 76 2.0 F
Coronary Occlusion, 
Coronary Atherosclerosis
Reference
Number
Age
Years
Cyclic AMP 
Creat ini ne 
Ratio 
nmols/mg
Fast / 
Slow 
Death
Cause of Death
19b 79 2.0 F
Myocardial Infarction, 
Coronary Atheroma, Hyper­
tensive Heart Disease, 
Adrenalcortical Adenomas
20b 53 1.8 F Myocardial Infarction, Hypertensive Heart Disease
21b 65 1.7 s
Myocardial Infarction, 
Coronary Atherosclerosis, 
Hypertensive Heart Disease, 
Hiatus Hernia
22b 75 1.4 F
Myocardial Infarction, 
Coronary Atherosclerosis, 
Chronic Bronchitis, 
Emphysema
23b 75 1.2 F Hypertensive Heart Disease
24b 77 0.9 F
Lung Abscess, Bronchopneu­
monia, Chronic Bronchitis, 
Emphysema
25b 44
COo F
Subarachnoid Haemorrhage, 
Ruptured Berry Aneurysm, 
Hypertension
26b 59 0.8 F
Myocardial Infarction, 
Coronary Atherosclerosis, 
Chronic Bronchitis
27b 75 0.7 F Cardiomegaly,, Fatty Disease of Liver
28b 54 0.5 F
Coronary Thrombosis 
Coronary Atherosclerosis
29b 17 0.5 F
Shock, Multiple Fracture 
of Lower Limbs & Pelvis
30b 78 0.2 S Anaemia, Macroglobulinaemia
31b 57 0 F
Myocardial Infarction, 
Coronary Atherosclerosis
32b 75 0 F
Myocardial Infarction, 
Coronary & Generalised 
.Atherosclerosis, Chronic 
Bronchitis, Emphysema, 
Congenital Absence of Right 
Kidney
Table 23 Cont'd
• (Female)
Reference
Number
Age
Years
Cyclic AMP 
Crcatini ne 
Rat i o 
nmols/mg
Fast / 
Slow 
Death
Cause of Death
33b 61 8.0 S Ruptured Aneurysm, Hypertensive Heart Disease
‘ 34b 15 6.6 F • Haemorrhage, Shock, Lacera­ted Heart & Liver, RTA
35b 69 CO F
Shock, Multiple Crash 
Injuries & Fractures, 
Consistent with RTA
36b 63 2.3 F
Coronary Occlusion, 
Coronary Atherosclerosis, 
Diabetes
37b 87 1.5 S
Bronchopneumonia, 
Hiatus Hernia
38b 81 1. 3 F
Myocardial Infarction, j 
Coronary Thrombosis, 
Hypertensive Heart Disease
39b 64
00o F Myocardial Infarction, Hypertensive Heart Disease
40b 60 o 00 S Bronchopneumonia, j Carcinoma Cervix
NB The ratios between the double lines are in the 'normal range'.
Drug Deaths and the Cyclic AMP/Creatinine Ratio
(Male)
Reference
Number Age
Cvclic AMP 
Creatinine Ratio 
nmols/mg
Drugs Involved 
in Fatality 
Overdose Unless 
Stated
Time Elapsed 
Between Person 
Being Last 
Seen Alive and 
the Discovery 
of the Body j
1 62 7.6 Amitriptyline *
2 38 6.3 Chlorpromazine *
3 36 5.6
A'mylobarbitone
Quinalbarbitone
Alcohol
*
4 49 5.6
Amylobarbitone
Quinalbarbitone
Pentobarbitone
! *
5 38 4.3
Amitriptyline 
Chloral hydrate 
(Therapeutic doses)
♦ .
6 32 4.1 Amylobarbitone (mental disorder)
*
7 66 3.7 Meprobamate 0
8 35 3.3
Alcohol
Glutethimide
+
9 21 3.3 Opiates *
10 57 3.3
Butobarbitone 
Amitriptyline 
(Therapeutic doses)
*
11 23 3.1 Orphenadrine *
12 45 2.9 Pentobarbitone *
13 54 2.7
Amylobarbitone 
Quinalbarbitone *
14 77 2.7
Amylobarbitone 
Quinalbarbitone *
15 51 2.5 Phosdrin *
16 28 2.5 Ethchlorvynol ?
17. 48 2.2
Quinalbarbitone
Nitrazepam
Alcohol
?
18 74 2.2 Aspirin *
Reference
Number Age
Cyclic AMP 
Creatinine Ratio 
nmols/mg
Drugs Involved 
in Fatality 
Over.dose Unless 
Stated
■t--------- • . ...
| Time Elapsed 
! Between Person 
i Being Last 
! Seen Alive and 
the Discovery 
of the Body
19 33 2.1 PentobarbitoneAlcohol
i
*
20 42 2.0 Aspirin • . *
21 35 1.9 Aspirin Alcohol .
*
22 36 . 1.7
Pentobarbitone
Alcohol 0
23 61 1.5 Cyanide *
> 24 79 1.4 Pentobarbitonp J *
25 64 i.l
Amitriptyline 
Therapeutic dose 
(Natural causes)
■-
.*
26 26 ! .0
Pentobarbitone
(Epileptic)
High Therapeutic
*
27 52 0.8 Aspirin *
28 43 0.7 Butobarbitone ?
29 46 . 0.5
Pentobarbitone
Alcohol 0
30 41 0.5
Amylobarbitone
Quinalbarbitone
Alcohol
♦
31 48 0.3
Alcohol
Chloral hydrate *
32 32 0.04 Diazepam *
33 45 0
Bronchopneumonia 
due'to overdose 
of drug Phenytoin 
caused death.
*
* Less than 48 hours between person being last seen alive and the 
discovery of the body.
0 More than 48 hours.
? Unknown as in most cases person lived alone.
NB The ratios between the double lines are in the ’normal range’.
(Female)
Reference
Number Age
Cyclic AMP 
Creatinine Ratio 
nmols/mg
Drugs Involved 
in Fatality 
Overdose Unless 
Stated
Time Elapsed 
Between Person 
Being Last 
Seen Alive and 
the Discovery 
of the Body
1 64 7.2
Amylobarbitone 
Quinalbarbitone 
(Nervous disorder)
*
2 57 7.2
Amylobarbitone 
Nortriptyli ne 
(Therapeutic dose)
?
3 . 16 5.8 Quinine *
4 21 5.3 Amitriptyline *
5 51 4.5 Pentobarbitone *
6 58 4.3 Pentobarbitone *
7 41 3.8 Dothiepin ?
8 21 3.7 Dichloralphenazone ?
9 26 3.4 Chloral hydrate (Theraeputic dose) ?
10 65 3.2 Paracetamol ?
11 46 3.1 Amitriptyline *
12 51 2.8 Amylobarbi tone Quinalbarbitone
*
13 52 2.4 Butobarbitone *
14 26 1.94 Chlormethiazole Imipr amine
. *
I5 27 1.8 Phenobarbitone *
16 43 1.66 Aspirin 0
17 53 0.78 ParacetamolChlormethiazole
*
18 68 0.3 Amylobarbitone *
19 48 0.13 Amylobarbitone ?
20 31 0.1 Quinalbarbitone Amylobarbitone *
21 46 0.05 Amylobarbitone 0
22 27 0.01 Amylobarbitone Quinalbarbitone ?
* Less than 48 hours between person being last seen alive and the 
discovery of the body.
0 More than 48 hours
? Unknown as in most.cases person lived alone.
NB The ratios.-bo tween the double lines are in the 'normal range?'.
SECTION 5 
DISCUSSION
5. DISCUSSION
5.1 Inhibition 'in vitro1 of Cyclic 3*5' Nucleotide 
Phosphodiesterase Activity by Drugs
Three of the most potent phosphodiesterase inhibitors 
were trifluoperazine, chlorpromazine and trifluopromazine, 
all of which are phenothiazine tranquillisers (Table 5 
p 47 ). Other drugs used for the treatment of- depres­
sion, eg the monoamine oxidase inhibitors (phenelzine and 
pargyline) and the dibenzazepine derivatives (imipramine, 
nortriptyline, amitriptyline and desipramine) inhibited at 
a concentration of 1 x 10“3M but the benzodiazepines, mep­
robamate and haloperidol had low activity. The hypnotics, 
sympathomimetic amines and analeptics had little or no 
activity with the exception of picrotoxin, which was one 
of the most active. Theophylline was found to be more 
active than caffeine. Of the other drugs known to have 
an effect on the brain, the hallucinogens were more active 
than the narcotics and analgesics. A9 tetrahydrocannab­
inol exhibited high activity inhibiting phosphodiesterase 
at the 1 x 10~Hl level. The most surprising result was 
the high activity of ascorbic acid,* since it is a normal 
dietary component and may be taken in large therapeutic 
doses.
If phosphodiesterase inhibition resulted in an 
increased urinary cyclic AMP excretion, these in vitro 
studies would indicate the drugs most likely to increase 
urinary cyclic AMP levels. However, direct extrapolation 
from in vitro, inhibition to an in vivo effect may not be 
possible because
(a) The drug way show a different order of inhibition 
towards other forms of phosphodiesterase.
Multiple forms of phosphodiesterase exist in a 
variety of tissues (Section 2 . 1 -p 21 ) and this appears
to be the rule rather than the exception. When different 
.forms appear in the same tissue most investigations 
indicate that two .main forms exist. The two* forms differ 
in many respects but mainly in their affinities for cyclic 
AMP; form 1 has a Km of the order 10"4M whereas form 2 has 
a Km of about 10”6M (Amer and Kreighbaum, 1975). Since 
the intracellular level of cyclic nucleotides is in the 
micromolar range or lower (Robison et al., 1970) Amer and 
Kreighbaum (1975) suggested that form 2 was more important 
for controlling cyclic AMP levels. Furthermore, 'Amer
(1973) has found,in hypertensive rats, an inverse 
correlation between intracellular levels of cyclic AMP and 
form 2 activity. Form 2 appeared to be particulate and 
this high activity form was suggested to be in equilibrium 
with the low activity soluble form, (form 1). It has 
been suggested that form 1 acts as a store of activity. 
Thus,unless in vitro studies on drug inhibition of 
phosphodiesterase refer to the high affinity form, the 
results may bear little relationship to the in vivo 
situation.
There also appear to be structural and kinetic 
differences between phosphodiesterases from different 
tissues. (Sheppard and Higgan, 1971). These differences 
are reflected in the different sensitivities to drugs 
(Honda and Imamura, 1968; Pichard et al., 1972;
Weinryb et al., 1972),
Protein activators of phosphodiesterase have been 
isolated from a number of tissues (Cheung, 1971; Schubart 
et al., 1973; Smoake et al., 1974) and it appears that 
drugs can affect the relationship between the activator 
and phosphodiesterase. Weiss et al*. (1974) reported 
that rat cerebral homogenates contained 4 different 
phosphodiesterase activities, referred*to as.peaks 1 to 4, 
which were separated by polyacrylamide gel electrophoresis. 
An activator affected peak 2 only, producing a ten fold 
increase in activity. Theophylline and papaverine 
.inhibited peak 2 before and after activation, whereas 
trifluoperazine had little effect on the unstimulated peak 
but showed a marked inhibition of the activated peak.
When the drugs were listed in the order of least potent 
to most potent inhibitor, the pattern differed for each 
peak. Moulin and Schultz (1975) also observed that an 
activated and unactivated phosphodiesterase from rat 
cortex showed different sensitivites of inhibition to 
drugs. Furthermore, the cyclic AMP concentration affected 
the inhibitory potency. The prevailing hypothesis is 
that the selectivity of phosphodiesterase inhibitors 
depends upon the different forms and the ratios of the 
multiple forms of phosphodiesterase in different tissues.
(b) The drugs may affect other parts of the cyclic AMP 
system.
Adenyl cyclase activity may be modified in numerous 
ways, eg at the catalytic site, receptor unit or by affecting 
the binding of an allosteric regulator such as cyclic GMP. 
Drugs may have similar effects on cyclic AMP-stimulated 
protein kinases. Furthermore, since more than one protein
kinase can occur in the same tissue, eg bovine thyroid
(Wilson and Malkin, 1974), drugs could selectively
modify the binding of cyclic AMP to these different forms.
Uzunov and Weiss ,(1971) showed that the phenothiazine
inhibition of noradrenaline-stimulated adenyl cyclase
(rat pineal gland) correlated with the pharmacological
potency of these tranquillisers..Palmer and Manian {1974a)
postulated that pharmacologically active phenothiazines
produce an anti-adrenergic action by inhibition of the 
♦
receptor component of adenyl cyclase. Other workers
/
•(Clement-Cormier et al., 1974; Karobath and Leitch, 1974) 
studying the inhibition by antipsychotic drugs of the 
dopamine-sensitive adenyl cyclase in mammalian brain, 
suggested that this was the site of action of these drugs 
(phenothiazines and benzodiazepines). Prada et al.
(1975) reported that lysergide increased the activity of 
adenyl cyclase in striatal homogenates of rats and proposed 
that it was the dopamine receptors that were stimulated.
There have been numerous reports of other drugs 
affecting adenyl cyclase, eg lithium, isoproterenol, ethanol 
(Section 2.4 p 37 morphine (Singhal et al. , 1973;
Puri et al., 1975), aspirin (Mangla et al., 1974) and lead 
(Nathanson and Bloom, 1975). The effects of salicylate 
and acetyl salicylate on bovine'diaphragm muscle protein 
kinase have been previously described (Section 2.4 p 39 ) • 
Removal of cyclic AMP from the cell may be one way 
of terminating its action and very little is known about 
this process. In a study on pigeon erythrocytes Davoren 
et al. (1963) found that cyclic AMP was secreted against 
a concentration gradient and the transport system was 
inhibited by probenecid. Therefore drugs could inhibit
or stimulate this extrusion process, hence prolonging 
or decreasing the intracellular effect of cyclic AMP.
This area needs further investigation,
(c) The pharmacological action of the drug may be at 
a different site and result in an indirect action on 
the cyclic AMP system.
Indomethacin, aspirin (anti-imflammatory 
drugs) and the antitumor drug estracyt are potent 
inhibitors of prostaglandin synthesis and this has been 
proposed as the mechanism of action of these drugs 
(Vane, 1971; Smith and Willis, 1971; Smith and Lands, 1971 
Perklov 1973). Since Kuehl et al. (1970) have suggested 
that the action of prostaglandins is mediated through 
cyclic AMP formation, these drugs may indirectly alter 
tissue levels of cyclic AMP.
Dolby and Kleinsmith (1974) noted that the effect 
of A9 tetrahydrocannabinol on mouse brain cyclic AMP 
levels could be correlated with known changes in 
biogenic amines. They proposed that A9 
tetrahydrocannabinol could alter the metabolism or 
transport of biogenic amines which are known to alter 
cyclic AMP levels (Section 2.4 p 36 ). Since the
action of tranquillisers and antidepressants can also 
be related to changes in brain amine metabolism or 
transport, indirect changes in tissue levels of cyclic 
AMP may be seen after ingestion of these drugs.
■(d) The drug may be metabolised to a form which has 
an augmented or decreased interaction with the cyclic 
AMP system when compared with the parent compound.
Garelis and Neff (1974) noted that Dopa produced a 
significant accumulation of cyclic AMP in the caudate nucleus of rats
and this accumulation was prevented by a Dopa 
decarboxylase inhibitor, ' These observations suggest 
that dopamine is the active agent. Dalton et al.
(1974) reported that the diazepam and oxazepam 
metabolites N-desmethyl diazepam and N-methyl 
oxazepam showed less inhibition of cat cortex 
phosphodiesterase than the parent compounds.
Palmer and Manian.(1974b) studied the inhibition
$
V ' by phenothiazines of adenyl cyclase from rat brain.
The dihydroxylated analogues of chlorpromazine, 
prochloperazine, perphenazine, promazine and the dioxo 
derivative:of chlorpromazine were more potent 
inhibitors of either basal activity or fluoride - 
activated enzyme than their parent compounds.
In conclusion, inhibition of phosphodiesterase is only 
one of the possible events that occur when drugs affect the 
cyclic AMP system. In this study it was probably the high 
Km form of the enzyme that was being inhibited, and this form 
may be unimportant in vivo. It is unlikely that both forms 
show the same inhibition characteristics because of the 
different kinetic characteristics and suggested locational 
differences. Furthermore, Amer and Marquis. (1971) have 
shown that adenosine potently inhibited form 2 in human 
blood platlets and had no effect on form 1. To date the 
importance of either form is only speculative and,if they 
are in equilibrium,the inhibition of one form may alter the 
activity of the other. The phosphodiesterase inhibition 
experiments described in this study are clearly far 
removed from the complexity of the situation in vivo.
iiOWever,? SOIIlfc! U± Lilt; mur e  ^uieui/ xnux.uj.tuio u.^3 uci/cu
in these experiments, eg phenothiazines, papaverine and the 
tricyclic antidepressants were also effective inhibitors of 
phosphodiesterases from a variety of other tissues 
(Section 2.4 p 35).
The experiments were therefore successful in that they
indicated the drugs which may alter cyclic AMP excretion by
inhibition of phosphodiesterase. Several of the more potent
inhibitors were ingested at a later date to determine whether 
they affected cyclic AMP excretion.
5.2 Validation of Experimental Procedures
(a) The Effect of Drugs on the Cyclic AMP and Creatinine
Assays
The lowest level of cyclic AMP found in a urine from a 
living person was 0.3nmols/ml. Since the standard deviation 
of measurement at this level is 0.03nmols/ml, and the maximum 
drug effect was never greater than an apparent level of 
0,02nmols/ml (Table 6 p 62 ), any false level caused by the
presence of drugs' can be ignored, .
In urines from drug deaths, levels of cyclic AMP as low 
as O.Olnmols/ml have been encountered. At this level of 
cyclic AMP drug effects would become significant and could 
result in a higher apparent cyclic AMP level being assayed than 
actually occurred in the urine sample.
However, none of the urines from overdose cases would 
either change from showing significantly high to normal, or 
normal to significantly low levels of the cyclic AMP to
creatinine ratio, if 0 .02nmols/ml were subtracted from 
the assayed cyclic AMP concentration.
The measurement of creatinine in urine samples was 
not affected by any of the drugs at the concentrations 
stated in Table 6 (p 62 )•
(b) The Stability of Cyclic AMP
Following the stability trials (Tables 7a,7b p64, 65). 
all urine samples were stored in the deep freeze and a 
maximum safe storage period of 3 months was observed.
For all practical purposes, the 3 sets of results 
(Table 8 p 67 ) indicated that cyclic AMP was stable in
the bladder for at least 3 days after the post mortem 
examination, with the provision that the bladder was 
stored at 4°C.
There is the possibility of a significant fall in 
bladder urinary cyclic AMP concentration between the time 
of death and the taking of the first urine sample (ie at 
the autopsy). This has not been resolved in the present 
study' and model experiments with animals would be required 
to reach a conclusion.
The study indicates that cyclic AMP is stable in 
urine stored in glass vials at room temperature for at 
least 3 days. Further it is shown that urines kept in 
the isolated bladder in a refrigerator for 3 days after 
the post mortem examination do not show a significant fall 
in cyclic AMP concentration. Thus, cyclic AMP is a far 
from labile material and these experiments indicate that 
a marked fall immediately after death is unlikely, espe­
cially as bladder contents are isolated from other tissues.
Phenyl mercuric nitrate with fluoride (Table 9 p 6 8 ) 
was the preservative chosen from studies on urinary cyclic 
AMP levels because
(a) these tablets were commercially available and 
thus a consistent amount of inhibitor could be 
conveniently added to the urine, and 
' (b) several laboratories from which urine samples
were to be obtained already used these tablets 
* . as a standard preservative. .
However, after 5 weeks storage at room temperature a 
urine sample with the phenyl mercuric nitrate and sodium 
fluoride tablet was reanalysed and a 7 fold increase in 
cyclic AMP concentration had occurred, ie 0.5 to 3.5nmols/ 
ml. It was suspected that either the phenyl mercuric 
nitrate complexed with,and precipitated cyclic AMP 
(endogenous and tritiated) leading to a low count rate and 
thus an apparently high cyclic AMP level, or the phenyl 
mercuric nitrate combined with groups on the protein (eg 
SH) and blocked the binding of cyclic AMP.
In an investigation of the mechanism of this apparent 
increase it was noted that the addition of mercurous or 
mercuric nitrate to urine samples could produce apparent 
increases in cyclic AMP content of a similar order.
Hydrogen sulphide bubbled through the urine success­
fully precipitated the mercury ions and the cyclic AMP 
level, in the test urine, then returned to its orignal 
level. ‘
In a repeat experiment with urines of varying pH from 
10 subjects, containing the. preservative tablet and 
stored in sealed containers for 6 weeks at room temperature, 
it was found that the cyclic AMP concentration did not vary 
with or without H 2S treatment. An examination of urines 
from the laboratories, all of which contained the preserva­
tive tablet, showed that about 5% had cyclic AMP levels 
which fell after. H2S treatment. Thus this artifact only 
applies to the minority of urine samples. The H 2S treat­
ment which does not affect cyclic AMP or creatinine, in the 
absence of mercury ions, was carried out as a routine 
procedure.
5.8 Cyclic AMP Excret ion
Several previous reports indicated that urine flow 
rate affects cyclic AMP excretion. Takahashi et al.
(1966) reported that water loading decreased cyclic AMP 
excretion, a result inconsistent with a later paper which 
suggested that the increased cyclic AMP excretion of manic 
patients was partially due to their increased urine volume 
(Paul et al., 1970b). Both reports contrast with experi­
mental results in rats (Hardman et al., 1969) and dogs 
(Goldberg et al.', 1969) in which extreme variations in 
urine flow rate had a negligible effect on cyclic AMP 
excretion.
The experimental results in Table 11 (p. 72 ) and
Fig 10 ( p 71 ) are in agreement with this negligible
effect in that doubling or almost trebling urine volume 
resulted in no consistent or significant change in cyclic 
AMP excretion. Flow rate is, therefore, not an important 
factor in determining the urinary excretion of cyclic AMP 
in man. .
As this study is concerned with the level of cyclic 
AMP in urine samples a normal range of levels had to be 
derived. * The less variable this normal range the more 
likely it is that factors which alter cyclic AMP. excretion 
will be detected. •
Cyclic AMP can be measured in terms of urinary concen­
tration or compared with an endogenous urinary compound.
The latter procedure was chosen (see Section 4.10 p 73), 
Creatinine was selected as the endogenous compound as it
- f . . |
was reported to be excreted at a consistent level over a 
24 hour period (Curtis and Fogel, 1970). Thecyclic AMP 
to creatinine ratio is considerably less variable than 
the concentration of cyclic,AMP in random urine samples 
(Section 4.10).
Folin (1904) originally suggested creatinine as an 
index of urinary excretion and estimated creatinine by the 
alkaline picrate method.
Creatinine is the cyclic anhydride of creatine (Fig 
17 p 118 ). The human body contains about 120g of
creatine/creatine phosphate, almost all of which occurs 
in skeletal muscle (Kleiner and Orten, 1958), where the 
formation and decomposition of creatine phosphate is an 
essential link in the transformation of chemical energy 
into.muscular work (Fiske and Subbarrow, 1929).
Creatinine is produced from creatine by a non-enzymatic 
dehydration process. The 24 hourly excretion of creat­
inine is not significantly altered by the amount of physical 
exercise; any increase in the excretion rate after 
particularly violent exercise is soon compensated for by
Creatine
Creatine phosphate
Creatinine
a i^eriod of lower excretion (Hunter, 1928). Van Pilsum 
and. Seljeskog (1958) noted that over shorter periods (3 
hours) exercise only increased creatinine excretion by 
up to 10%. Ingested creatinine is mostly excreted in 
the urine unchanged but normal diets contain only a trace 
of creatinine. Creatinine excretion can be increased by 
ingesting large amounts of creatine (Rose and Dimmit, 1916) 
or its amino acid precursors (Beard and Barnes, 1931), but 
this is not relevant when considering normal diets. Lean 
meat contains the highest amount of creatine in the diet 
(ie about 0.5%, Plimmer et al., 1909). The average daily 
intake of meat in Europe (Domestic Food Consumption 
Expenditure, 1961; British Ministry of Agriculture, 
Fisheries and Foods, 1963) and North America (Sunderman 
and Boerner, 1950) is 100 - 200g containing not more than 
lg of creatine. Even if this was ingested as pure creat­
ine it would only lead to the excretion of O.lg of creat­
inine (Rose and Dimmit, 1916). Van Pilsum and Seljeskog 
(1958) found that the ingestion of 300g of well cooked 
meat increased, clearance values by only 10%.
In normal circumstances creatinine passes"into the 
urine only by glomerular filtration. Tubular secretion 
is not important unless the level of creatinine in blood 
plasma is artificially raised to a level of 5-10mg/100ml 
which is 5-10 times the normal physiological concentration 
(Peters and Van Slyke, 1946). Urine flow rate variations 
were found to have no effect on creatinine excretion (Van 
Pilsum and Seljeskog, 1958). More creatinine is excreted 
by men than women with approximate means of 1.7g (828 sub­
jects) and l.Og (130 subjects) per 24 hours respectively 
(Jackson, 1965). ' ..
creatinine in 12 subjects over 4, 8 and 24 hour periods.
Over the 24 hour period excretion was remarkably stable 
for a biological compound, (ie coefficients of variation 
3.7 to 14.3%). However, in the 4.hour or 8.hour collec­
tion periods coefficients of variation 9.4 to 28.7%* were 
detectable. Another group found slightly greater coef­
ficients of variation in 24 hourly cyclic AMP excretion 
ie 5,6 to 22.3% (Edwards et al, 1969), Babies have a very 
low creatinine excretion rate as shown in Table 25 (p 121) 
which increases through childhood and adolescence. Normal 
individuals over the age of 60 may have a reduced 
creatinine clearance (Van Pilsum and Seljeskog, 1958).
Creatinine excretion can also be altered by disease 
states. An increased blood level was reported.in 
hypertension (Sen, 1965) and an increased urine level in 
obesity (Konishi and Torres, 1964) renal damage (Della- 
Santa et al., 1968) and Werdnig-Hoffman muscle disease 
(Chlap and Hornik, 1958). In contrast a.decreased blood 
level has been observed in Osteogenesis imperfecta 
(Chowers et al. , 1962) and a decreased urine level in 
muscular dystrophy (Noboru et al., 1968) and schizophrenia 
(Yuwiler, 1969; Subra Hosanyan et al., 1962). Diuretics, 
eg acetazolamide and hydrochlorothiazide, have also been 
shown to increase the urinary level of creatinine 
(Manganelli and De Salvia, 1962),
A significant change in the cyclic AMP to creatinine 
ratio may therefore be due to disease or drugs altering 
creatinine rather than cyclic AMP excretion. As far as possible creat­
inine clearance values should be checked before attaching significance
* Coefficient of variation of 28.7% could mean as much as a 
4 fold difference in the creatinine excreted over the stated time period.
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to marked changes in the cyclic AMP to creatinine ratio.
In this study the subjects who gave urine samples, 
for the calculation of the cyclic AMP to creatinine 
ratio, were in the age range 20-60 years. The normal range 
of the ratio for men was found to be 1,3 to 4.5nmols/mg 
(Section 4.10) which agrees with that published by 
Kaminsky et al. (1970a) who quoted a range of 1.5 to 
5.0nmols/mg (males aged 20-30 years).
Taylor et al. (1970) stated that there was no 
significant difference in the 24 hourly excretion of cyclic 
AMP for men or women and thus, it would seem logical that 
the mean cycle AMP creatinine ratio will be greater in 
women than men because of decreased creatinine excretion.
In this study the mean value for women was 4.3nmols/mg 
and for men 2.9nmols/mg,
Higher mean cyclic AMP to creatinine ratios were found 
in children's urines and several of the ratios were well 
outside the normal ranges for men and women (Table 14 
p 74 ). August and Hung (1973) also detected a higher 
cyclic AMP to creatinine ratio in children (up to 
llnmols/mg in a 24 hour sample). This increased ratio 
figure is a reflection of the decreased creatinine excretion 
of children (Table 25 pi21>). Children were not investigated 
any further in the present study because of their decreased 
creatinine excretion.
Generally research workers have been fairly consistent 
in their reports regarding daily excretion of cyclic AMP 
(Table 3 p 29 ). These figures agreed well with the mean
24 hourly levels for subject I (3.9jjmols) and subject II 
(4.1ymols). Considering the interassay coefficient of 
variation of ±11%, the coefficients of variation of 6.7% 
and 14%, for subjects I and II respectively, indicate a 
consistent excretion of cyclic AMP over the 24 hour 
period.
The slight variation in the 24 hourly level is in 
agreement with Murad and Pak (1972) who studied patients 
for periods of several weeks and found less than 20% 
variation in their daily excretion of cyclic AMP.
A slight circadian rhythm in the excretion of 
cyclic AMP was observed for both subjects, in each case 
there was approximately a 20% decrease during the nocturnal 
period (Table 15 p 76). Chase et al. (1969) found no 
diurnal variation in the urinary excretion of cyclic AMP 
(4 subjects) during 4 hour periods, for a total time of 
48 hours. In contrast Murad and Pak (1972, y unspecified 
no of subjects) and Holmes et al. (1973, 28 subjects) have 
both observed a diurnal variation in cyclic AMP excretion. 
The latter authors reported 2 populations in terms of plasma 
cyclic AMP, the 4 hourly urinary excretion values showing 
some variation (ie in the range 300 - 400nmols cyclic AMP).
At the present time there is no agreement on a 
distinct circadian excretion pattern for urinary cyclic AMP, 
and workers reporting a pattern differ in the times of  ^* 
maximum and minimum excretion. It may be that some people excrete 
at a constant rate whilst others vary considerably in their 
excretion rate. There is, however, no doubt that cyclic AMP
excretion varies throughout the day and this is one of 
the factors contributing to a "normal range" of cyclic 
AMP to creatinine ratios. Both subjects in the present 
study appear to be constant excretors which simplifies the 
detection of a factor that can influence cyclic AMP 
excretion. From figures 12a and 12b (p80,8f), subjects I 
and II have mean hourly cyclic AMP to creatinine ratios 
•of 2.5nmols/mg (coefficient of variation 8.4%) and 3.1nmols/ 
mg (coefficient of variation 11%) respectively. Thus 95% 
confidence limits produce normal ranges of 2„1 to 2.9nmols/ 
mg and 2.4 to 3.8nmols/mg for subjects I and II respectively. 
From the larger batch of urine samples (1 hour, 8 hour and 
24 hours) these ranges become 1.8 to 3.2nmols/mg and 1.8 
to 3.6nmols/mg. In practical terms, therefore, there are not 
significantly larger changes in the cyclic AMP to creatinine 
ratios for the 1 hour as compared with the larger collection 
periods.
A significant change in the cyclic AMP to creatinine 
ratio for subjects I and II can be considered in terms of 
being either significantly different from the male population, 
ie falling outside the range 1.3 to 4.5nmols/mg (n = 100,
95% confidence limits, Section 4.10) or being significantly 
different from the individuals1 ranges, ie 1.8 to 3.2nmols/ 
mg and 1.8 to 3.6nmols/mg respectively. The values 
obtained after a variety of procedures were tested using 
both these criteria. As can be seen for both subjects a 
50% decrease or 100% increase of their mean cyclic AMP to
creatinine ratio values (2.5 and 2.7nmols/mg respectively) 
produce values outside the normal range of the population 
investigated.
Subject I*s-hourly urine pH values were normally 
between 5.0 and 7.0 and subject II1s between 5.5 and 7.5.
The pH values vary widely within this range for both 
subjects. However, maintaining the pH above 7 does not 
significantly (ie beyond the normal range, mean ±2 standard 
deviations) alter the mean 24 hourly excretion level of 
either subject (Section 4.12 p 79 ),
In the experiments of Eccleston et al. (i.970), which 
included 5 - 10 mile walks over rough hilly tracks, 24 hourly 
cyclic AMP excretion was found to increase with exercise..
In two of their walkers it almost doubled. Holmes and 
Hartman (personal communication) have noted marked short 
term increases in plasma cyclic AMP levels after exercise 
on the Harvard Step. However, no increase in urinary cyclic 
AMP was noted during the period of an hour or more which 
included the exercise. Subjects I and II showed no 
significant effects of exercise as both the amounts of cyclic 
AMP excreted during 24 hours and also the cyclic AMP to 
creatinine ratios were within normal variation limits 
(Table 16 p 83 ). These results are in agreement with those 
of, Murad and Pak (1972) who stated .that exercise had no 
effect on the total amount of cyclic AMP excreted. A similar 
lack of effect has been reported by Paul et al. (1971b) in 
a study of hyperkinetic children and by Sinanan et al. (1975) 
in a study of cyclic AMP excretion in 4 hour periods with 
and without exercise.
The 3 physiological factors examined in this work 
were urine flow rate, pH change and-exercise. None of these 
factors significantly influences cyclic AMP excretion..
The major sources of both plasma and urinary cyclic 
AMP are still far from clear even though it is now almost 
20 years since the discovery of cyclic AMP. Broadus et al. 
(1970) reported that about a third of urinary cycTic AMP 
is of kidney origin, the rest coming from the plasma 
(Section 2.3 p 25 ). The liver, kidney and central nervous 
system appear to be possible sources of plasma cyclic AMP 
(Section 2.3 p 28 ).
After an intravenous injection of a known amount of 
radioactively labelled cyclic AMP into a volunteer only 20% 
appeared in the urine (Broadus et al. 1970a). What happens 
to the remainder? Is the other 80% metabolised or 
excreted via other routes such as bile? Strange and Percy-Robb 
(1975) showed that after intravenous injection of tritiated 
cyclic AMP into rats it quickly disappeared from the plasma 
(| life * 8 mins). In 15 minutes approximately 11-16% of 
the dose appeared in the liver with about 0.15% appearing 
in the bile after an hour. Accumulation of similar amounts 
of radioactivity in the liver 15 minutes and 60 minutes 
after injection suggested that the uptake was fairly rapid 
and that cyclic AMP was converted to nucleotides that were 
not so readily released. Even though the time period was 
short the authors suggested that bile is not a major source 
of excretion. There do not appear to be any studies on 
the bilary excretion of cyclic AMP in man. Blonde et al.
(1974) have also shown that liver can rapidly remove cyclic
AMP from plasma. The mechanism of hepatic absorption is 
unknown.
Since urine could only account for two thirds of the 
total kidney clearance of tritiated cyclic AMP infused into 
dogs, the kidney has also been suggested as a site of 
metabolic clearance of cyclic AMP. (Blonde et al., 1974). 
Coulson et al. (1974),. studying rats before and after 
nephrectomy, also found that the kidney both metabolised 
and excreted cyclic AMP. Perfused rat kidney absorbed extra­
cellular cyclic AMP by a transport system that could be 
blocked by probenecid (Coulson and Bowman, 1974).
It appears that liver, and possibly other organs, 
rapidly absorb and metabolise plasma cyclic AMP, which would 
account for its rapid disappearance from the plasma (£ life 
of approximately 32 minutes, Section 2.3 p 26 ), and
hence, only 20% appearing in the urine. There is little 
information on the excretion of cyclic AMP from cells into 
plasma.
The amount of urinary cyclic AMP excreted in 24 hours 
is remarkably constant (Section 4.11 p 75) and this would 
appear to be a reflection of the carefully controlled 
hormone balance in the body. Circumstances in which cyclic 
AMP excretion are altered must therefore be considered,if : 
this compound is used as a biochemical marker. There are 
many reports of disease states affecting cyclic AMP 
excretion.
Chase and Aurbach, (1967) were the first to note that 
parathyroid hormone injection produced a marked increase in 
the urinary excretion of cyclic AMP in rats. Tomlinson 
et al. (1974) have shown that the injection of purified
bovine parathyroid hormone into normal human subjects 
increased the concentration of cyclic AMP in the peripheral 
plasma within minutes. The concentration of cyclic AMP in 
renal vein plasma increased more rapidly than that in 
peripheral plasma. Therefore, these authors suggested 
that the kidney was an important source of the changes in 
plasma cyclic AMP induced by parathyroid hormone. Anephric 
subjects failed to show an increase in plasma cyclic AMP 
after parathyroid hormone. There have been several reports 
showing that increased and decreased urinary cyclic AMP 
excretion occurred in hyperparathyroidism and ! 
hypoparathroidism respectively (Section 2.3 p 27 ).
Pseudohypoparathyroidism was suggested to be a hormone 
disorder resulting from a defective adenyl cyclase receptor 
in the kidney cortex (Chase and Aurbach, 1967). Lilienfeld- 
Toal et al. (1974) studied the urinary excretion of cyclic 
AMP in human subjects with chronic renal failure and primary 
hyperparathyroidism. After parathyroid hormone infusion 
normal subjects showed a greater increase in cyclic AMP 
excretion than patients with renal insufficiency. The 
increases observed in the latter were inversely related 
to the degree of kidney failure. In patients with primary 
hyperparathyroidism a diminished increase in cyclic AMP 
excretion was observed after parathyroid hormone infusion. 
Bartley et al. (1975a) noted that patients with primary 
hyperparathyroidism excrete more urinary cyclic AMP than 
normal subjects. However, normocalcemic hyperparathyroid
subjects and hyperparathyroid subjects with renal 
insufficiency could excrete daily quantities of cyclic 
AMP within the normal range. Bartley et al. (1975b) also 
studied urinary cyclic AMP excretion in 14 patients with 
hypercalcemia not caused by primary hyperparathyroidism.
The different types of hypercalcemia could be classified 
according to a normal, high or low 24 hourly cyclic AMP 
excretion.
It *was previously mentioned that cholera toxin can 
overstimulate intestinal cyclase (Section 2.3 p 30 ).
Cholera toxin which was infused into a branch of the renal 
artery in a dog (thyroid-parathyroidectomised) increased 
urinary cyclic AMP from both kidneys, the infused showing 
more response than the control kidney (Friedler et al.,
1975). The adenyl cyclase activity of the infused kidney 
was slightly higher (109-142%) than the control kidney.
In epidermis,adenyl cyclase is stimulated by 
catecholamines and prostaglandins of the E series which act 
at separate sites. In psoriasis the response of adenyl 
cyclase to these regulators, especially the catecholamines, 
was reduced (Halprin et al., 1975). However, the 
concentration of cyclic AMP in the epidermis of a psoriatic 
lesion appeared to be no lower than in non. involved skin.
The mechanism by which cyclic AMP controls proliferation or 
differentiation is unclear. Stawiski et al. (1975) suggested . 
that the low lesional ratio of cyclic AMP to GMP in psoriasis 
might be important and these workers used papaverine (1% cream), a
phosphodiesterase inhibitor, to treat psoriasis. This 
treatment resulted in significant improvements in the 
psoriatic lesion. Langier et al. (1973) treated psoriasis 
with topical dibutyryl cyclic AMP and theophylline but 
achieved only a modest improvement. In contrast, daily 
intramuscular injections of dibutyryl cyclic AMP produced a 
significant improvement in severe psoriasis. (Anonymous, 
Shanghai Biochem.Res, Inst., 1974). No values seem to be 
available on the urinary excretion of cyclic AMP in psoriasis.
Adrenaline administration induced a two fold increase 
in urinary cyclic AMP in normal subjects and no appreciable 
increase in asthmatics. Whereas, glucagon induced a four 
fold increase in urinary cyclic AMP for both groups 
(Bernstein et al. , 1970). The different responses of ■>. 
asthmatics and normal subjects to adrenaline and glucagon 
supported the hypothesis that asthma was due to a defect 
of the system in which cyclic AMP was-formed by 8-adrenergic 
stimulation. However, basal (ie non-stimulated) levels of 
cyclic AMP in urine did not significantly differ between 
asthmatics and normal subjects.
The effect of depression and mania on the urinary 
excretion of cyclic AMP has been previously reviewed <
(Section 2.3 p 31 ). In experiments on rats it was
observed that mental stress (loud bell ringing) did not alter 
.hypothalamic or adenohypophyseal cyclic AMP content.
Whereas, physical stress (stream of nitrogen passed over 
the rats) significantly decreased cyclic AMP levels in the 
hypothalamus and significantly raised cyclic AMP levels in
the adenohypophyseal tract (Siegel et al., 1974).
These observations suggest that cyclic AMP in the 
hypothalamic or adenohypohyseal tract changes according to 
the type or degree of stress imposed. Thus cyclic AMP may 
play an important role in the response of the hypothalamic - 
pituitary tract to stress. More recently Delapez et al.
(1975) showed that stress (electric shock or restraint) 
increased the level of cyclic AMP in various areas of the 
rat brain. There were marked increases in the septum and 
smaller increases in the hippocampus and brain stem. 
Previously cyclic AMP changes in the central nervous 
system were reported to be reflected in urine (Abdulla and 
Hamadah, 1970; Paul et al., 1970). Therefore it is possible 
that stress affects the urinary excretion of cyclic AMP.
Heikkinen et al..(1974) studied 84 neurological 
patients and noted that the average concentration of cyclic 
AMP in the CSF from female patients was significantly 
higher than that from males. Some of the disorders could be 
distinguished by reference to the associated CSF cyclic AMP 
concentration. Myllyla et al. (1975) noted that in active 
or progressing CNS damage the cyclic AMP levels in CSF 
were significantly higher than those with previous CNS 
damage. Thus CSF cyclic AMP was significantly elevated 
after epileptic attack when compared with epileptic patients 
who were free from attacks for several weeks.
Hamet et al. (1973) observed an increase in the urinary 
cyclic AMP of labile hypertensives in response to the 
upright position and after isoproterenol infusion. This 
increase was in contrast to a decrease in control subjects.
However a later study (Harriet, et al. , 1974) showed that the 
plasma cyclic AMP level rose in both controls and labile 
hypertensives in response to upright posture or iso­
proterenol infusion. It wouid appear that kidney handling 
of cyclic AMP differs in labile hypertensives and control 
subjects.
In renovascular hypertension the plasma cyclic AMP 
levels were higher in both the recumbent and upright posture 
than in labile hypertensives and there was a normal 
urinary cyclic AMP in both these positions. In a third 
type of hypertension, phaeochromocytoma, a rapid release of 
catecholamines occurs, and this led to a significant 
increase in plasma cyclic AMP. When the subjects were not 
experiencing an attack plasma levels of cyclic AMP were 
comparable to those of normal subjects. Therefore, 
different types of hypertension have characteristic 
alterations in urinary and/or plasma cyclic AMP.
It was previously mentioned (Section 2.3 p 30). 
that in diabetes mellitus an increased 24 hourly cyclic 
AMP excretion was observed. In nephrogenic diabetes 
insipidus an adenyl cyclase disorder similar to that 
occurring in pseudohypoparathyroidism has been observed. 
However, the changes observed after ADH administration 
are not clear. Bell et al. (1974) studied 4 water-loaded 
normal subjects, 1 ADH deficient patient and 3 nephrogenic 
diabetes insipidus patients. Intravenous ADH increased 
the mean urinary cyclic AMP excretion of the normal and ADH 
deficient subjects and also changed the urine osmolality.
In contrast, ADH did not alter the urinary cyclic AMP 
or osmolality of the nephrogenic diabetes insipidus 
patients, suggesting a defective adenyl cyclase system.
Rail et al. (1974) studied 7 ADH deficient (central diabetes 
insipidus) children, 3 with nephrogenic diabetes 
insipidus and 5 normal children. Excretion of cyclic AMP 
was depressed in both types of diabetes insipidus. 
Administration (intramuscular) of ADH decreased the absolute 
rate of cyclic AMP excretion in ADH deficient and normal 
children but had no effect in nephrogenic diabetes 
insipidus children. The situation remains confused as to 
whether urinary cyclic AMP increases or decreases in normal 
subjects after ADH.
In children with cystic fibrosis the urinary cyclic 
AMP to GMP ratio (4.4 ± 0.32 mean ±SE) was significantly 
lower than normal children (9.09 ± 0.5), and was a 
reflection of increased cyclic GMP excretion (Murad et al., 
1975).
Survivors of acute myocardial infarction had slightly 
raised levels of plasma cyclic AMP which returned to normal 
after 24 hours. In contrast non-survivors had significantly 
raised levels of cyclic AMP which did not return to the 
normal range even after 7 days (Rabinowitz et al., 1974).
The cyclic AMP concentration was inversely correlated with 
the stroke work index (value obtained from intra arterial 
pressure and cardiac output). The plasma levels of cyclic 
AMP in this study were compared with normal volunteers and 
patients with other cardiac and non-cardiac diseases.
Plasma levels of cyclic AMP were found to be 
significantly higher (58nM) in subjects with severe 
renal -failure than in 15 normal subjects (23nM) (Hamet 
et al.y 1975). Plasma clearance decreased from 
624 ml/min to 344ml/min and in these uremic subjects 
plasma production of cyclic AMP was 65% higher. The 
elevated plasma level was suggested to be due to
a) lack of urinary excretion b) decreased metabolic 
clearance and c) increased production of plasma cyclic 
AMP.
As the plasma concentration of cyclic !AMP was high 
in patients with idiopathic oedema, and its renal 
clearance was low, Kuchel et al. (1975) suggested that 
the renal handling of cyclic AMP was abnormal in this 
condition.
Low tissue levels of cyclic AMP have been associated 
with cancer (section 2.3 p 31 ) and this correlates with 
low tissue levels of cyclic AMP stimulating cell 
proliferation (Otten et al., 1972; Froehlich and 
Rachmeler. 1972)
Drug Ingestion and Cyclic AMP Excretion
For all practical purposes the small increases in 
the 24 hourly cyclic AMP level after consumption of 
alcohol are insignificant (Table 17 p 84) especially 
in the light of the 24 hourly levels of 2-7ymols 
published by Butcher and Sutherland (1962). The 
ingestion of ethanol caused no significant change in 
the cyclic AMP to creatinine ratio (outside normal 
male population range).
The alterations in the cyclic AMP to creatinine 
ratio which occur after administration of ascorbic acid 
to subject II were significant .in terms of his normal 
excretion range but not significant in terms of the large 
population studied (Table 18 p 87 ). It is possible that 
slight increases in the 24 hourly excretion level and 
cyclic AMP to creatinine ratio observed for subject II 
could be explained by inhibition of phosphodiesterase 
(Moffat et al., 1972), On the other hand,2g of caffeine 
(ie 200mg per cup of coffee and tea) has no significant 
effect on 24 hourly cyclic AMP excretion (Section 4.16 
P 86).
After amphetamine, amylobarbitone, imipramine and 
trifluoperazine administration, only amphetamine and 
trifluoperazine produced significant increases in 24 
hourly excretion. The increases just exceeded 2 standard 
deviations from the mean 24 hourly level of subject II 
(Table 19 p 92 ). These drugs also shifted the cyclic 
AMP to creatinine ratios outside the normal range for 
subject II in several of the 2 hourly urine samples.
All these changes in the ratio were within the normal 
range for the male population studied and are therefore, 
in practical terms, insignificant. The slight increases 
in the 24 hourly excretion level were also, for any 
practical purposes, insignificant. From previous work on 
in vitro inhibition of phosphodiesterase (Section
4.1 p 46). it was expected that drugs such as caffeine,
imipramine and trifluoperazine might have had an effect 
on the excretion of cyclic AMP in the urine. There may 
be several reasons why this did not occur (see Section
5.1 p 107). There remains, of course, the possibility 
that drugs may have to be taken in overdose rather than 
therapeutic quantities before an effect on cyclic AMP 
excretion is observed.
Several studies have indicated that drugs can 
alter cyclic AMP excretion. Keatinge et al. (1975) treated 
rats (chronic dosage) with reserpine, chlorpromazine, 
imipramine and amitriptyline. Reserpine decreased the 
urinary excretion of cyclic AMP whereas the tricyclic 
antidepressants, imipramine and amitriptyline led to an 
increase in excretion. Chlorpromazine showed no appreciable 
effect. These results paralleled findings in humans where 
urinary cyclic AMP was decreased in depression and increased 
by successful antidepressant therapy. Heikkinen et al. 
(1974) stated that there was a tendency for cyclic AMP 
concentration to increase in the CSF of males after 
ingestion of papaverine or theophylline and of females 
ingesting phenothiazines or benzodiazepines. No changes 
were detected in urine. A therapeutic dosage of 
chlorpropamide decreased slightly the excretion of cyclic 
AMP in patients with either central or nephrogenic 
diabetes insipidus (Raij et al., 1974).
Acetazolamide (3mg) increased urinary excretion of 
cyclic AMP in rats (normal and parathyroidectomised).
This was not due to a change in urine flow rate or pH.
It was suggested that acetazolamide stimulates, renal 
cortical adenyl cyclase (Rodriguez et al., 1974),
The studies concerned with cyclic AMP excretion, 
after drug ingestion, or in certain pathological conditions, 
fall into two categories,
a) where an alteration in urinary or plasma cyclic AMP 
was observed
b) where altered tissue or CSF levels of cyclic AMP 
were observed.
As the present study is concerned with urinary levels 
of cyclic AMP, category "a".drugs and diseases are more
important than those of category "b", which may not result 
in altered plasma or urinary levels of cyclic AMP.
In conclusion, a biochemical marker for drug 
overdosage would have to be excreted at a reasonably 
consistent level under normal conditions. Cyclic AMP 
appears to fulfil this criterion since its excretion is not 
significantly affected by physiological factors such as 
urine flow rate, pH and exercise or ingestion of 
therapeutic doses of many commonly used drugs. However, 
one must exercise caution when interpreting abnormal 
urinary levels of cyclic AMP because certain disease 
states and therapeutic doses of a few drugs are capable of 
altering cyclic AMP excretion.
5:4 Chemical Changes associated with Death
How can death be defined biologically? Death can 
be considered in terms of an organ, a tissue, a cell or an 
enzyme. Dying appears to be an increasing loss of 
organisation of the body, starting at the higher centres and 
progressing down through the tissues, cells and enzymes.
The process ultimately becomes irreversible. In the search 
for a definition,the level of organisation becomes an 
important factor, thus in transplantation a living organ is 
removed from a dead body. A clinical definition of death 
could be ".that state of the whole body in which the brain 
irreversibly loses control of the spinal chord” (Hillman, 
1970). However, when is this change irreversible?
Hillman (1974a), after observing dying patients and animals
has defined three overlapping stages of dying.
1) The first was the excitatory or motor stage 
induced by pain, stress, the agent causing death
or hypoxic depolarisation of the central nervous
system. Characteristics were violent muscular 
activity, pulse and, respiratory rate rise, 
increased blood catecholamines and sweating. 
Hillman stated that this stage was probably 
reversible if one could supply oxygen to the 
nervous system sufficiently rapidly.
2) The second stage consisted of enormous autonomic 
nervous activity followed by exhaustion. 
Characteristics were pilo-erection, sweating, 
micturation,defaecation, loss of vasomotor
tone of the arterioles, dilated pupils and a
fall in the temperature of the body. This 
stage was reversible'if caused by hypothermia but 
it is not known whether it is reversible if due to 
other agents.
3) The third stage was typified by a complete 
collapse of internal organisation in which 
hypoxia had- reached the peripheral tissues. 
Characteristics included cardiac arrest, muscle 
relaxation, the cessation of peristalsis and 
individual organs losing viability at different 
rates. The electrochemical gradient between 
extracellular and intracellular fluids disappeared 
Na+ flowed from the plasma into the cells and 
K+ flowed in the opposite direction. The tissues 
lost their resistance to infection and finally 
putrefaction occurred.
This third stage is recognised as irreversible and 
within the sequence is the point identified by physicians as 
death. Evans (1963) has reviewed post mortem changes in 
detail. Organisms migrated from the gut and the lungs along 
the lymphatics, capillaries and tissue planes. These 
organisms, as well as autolysis, led to the break down of 
fat, protein and carbohydrate. All these changes proceeded 
more rapidly in the presence of warmth and moisture. The 
organisms initially involved were aerobic bacteria eg 
staphylocci. As there was little access to oxygen deep in 
the tissues the aerobic bacteria were gradually 
replaced by anaerobic bacteria such as Clostridia.
Fungi tended to grow in the acidic conditions produced
by the build up of lactic acid. Gas produced, by these
organisms swelled the tissues and in the absence of 
refrigeration the face and other normally identifiable 
parts of the body became unrecognisable. This putrefactive 
process continued until eventually the remains consisted 
of little more than the harder resistant tissues of bone, 
teeth, cartilage, lens, hair and nails.
The general practitioner uses several criteria to 
diagnose death. The major ones of these are listed below. 
Circulatory arrest, indicated by the absence of the radial 
and carotid pulses, and absent heart sounds on auscultation.
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In hospitals this may be supplemented by the electro­
cardiograph. Apnoea can be detected by holding a cold 
mirror near the lips and noting the lack of respiration.
Glassy cornea, dilated pupils, coldness of skin, pallor 
or cyanosis of skin and absence of reflexes are also used.
However in the last decade, transplantation of kidneys, 
lungs, livers and hearts has raised the question of when can 
one really say that a patient is dead? Hence, the concept 
of brain death has been conceived, a condition in which the 
brain is so badly and irreversibly damaged that the person 
could not possibly recover from a vegetative existence. 
Criteria for brain death include clinical evidence of severe 
damage to the central nervous system, flattened 
electroencephalogram for many hours, radiological evidence 
of brain damage such as that derived from arteriography 
or air encephalography and a relevant clinical history 
(Juul-Jensen, 1970). The difficulty of course is that the 
person is still breathing and has a heart beat, which are
the historical criteria for life. An attempt has been 
made to avoid this difficulty by suggesting an intermediate 
certification of irreversible brain damage which would be 
verified by doctors representing relatives of the patient 
(Hillman and Aldridge, 1972).
Relatively little is known about the biochemistry of 
death. The brain has been studied more than other organs 
(Gaevskaya 1964; Negovsky, 1962; Leonard and Hillman 
1972). Hillman suggested that there was a massive stress 
reaction resulting in the release of catecholamines and 
corticosteroids. This has not, however, been demonstrated 
biochemically. The cerebral ATP, phosphocreatinine and 
glucose levels fell dramatically, the last to virtually 
zero. The cerebral lactate level rose, although animals 
could recover from high venous lactate levels. (Rogers and 
Hillman, 1972). Cerebral K+ and Na+ concentrations both fell 
slightly, probably because of cerebral swelling. Serum K+ 
rose and Na+ fell as both ions depend upon a functional 
energy pump. Nevertheless all these cerebral changes could 
be detected during convulsions and mimicked in cerebral 
slices (Mcllwain and Rodnight, 1962). In these cases the 
changes could be reversed. Thus there is the enigma of the 
irreversibility of death and the reversibly linked changes 
in the tissues. Are these changes the triggers or 
consequences of death? What is the critical biochemical 
change in this sequence? At the molecular level little is 
known about death. The active processes occurring during 
life are involved in establishing a low entropy state which 
is necessary to maintain an organised system. This
organisation involves compartmentalisation by membranes.
The membranes have active rather than passive roles.
The lack of energy to maintain membranes leads to a loss 
of membrane integrity and results in entropy rising to a 
non-recoverable level. New mixtures fill the cells and the 
extracellular spaces and it is assumed that irreversible 
changes in the macromolecules, probably proteins, occur. 
Death may be considered as membrane perturbation exceeding 
a critical limit.
The simplest hypothesis for death at the tissue level 
is anoxia and all changes are seen as secondary to this. 
There are several forms of anoxia,
a) anaemic form
lack of red blood cells or change in conformation 
of haemoglobin producing impaired oxygen 
carriage,
b) stagnant form
slowed blood current fails to carry a sufficient 
amount of oxygen,
c) anoxic form
interference with blood oxygen transfer eg in 
pneumonia or pulmonary oedema,
d) histotoxic form
interference of the use of oxygen by the tissues. 
All these forms would prevent tissues from generating the 
necessary energy for life via oxidative phosphorylation.
A mechanism by which anoxia causes death has been 
proposed by Rogers and Hillman. (1970) and was based on a 
series of experiments in which rats were cooled to achieve
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It was found that in severely hypoxic rats, which did not 
survive, the blood pressure fell about a half minute 
before the heart stopped. In contrast in less hypoxic 
rats, with a high rate of survival, the heart stopped and 
then the blood pressure fell. Hypoxia plus cold were 
suggested to cause irreversible blockage of the 
baroreceptor reflexes and in chemical reactions 
involved in local vasomotor tone. This produced a massive 
vasodilation similar to that found in normothermic shock. 
The blood was pooled peripherally, which has been shown to 
occur in death, leaving an inadequate supply in the central 
circulation. Thus the venous return was reduced and this 
caused the heart to fail. The collapse in blood pressure 
could not be prevented by hypertensive drugs but was 
reversed by immediate application of artificial 
ventilation with air. So although cardiac contractility 
might return there was not enough blood in the system 
"to prime the pump” . Hillman (1974b) states that it is 
generally held among clinicians that, at ordinary 
temperatures, cardiac arrest of 4 minutes duration or more 
causes irreversible brain damage and cellular changes 
have been detected with an electron microscope.
Therefore, hypoxia not only stops the vital processes 
but if sufficiently severe leads to irreversible 
disorganisation. However,at this stage it would be rather 
dogmatic to say that anoxia is the final cause of de'ath, 
because the biochemical changes, let alone the critical 
change, that occur when anoxia preceeds death are unknown.
, Poisoning may ultimately produce anoxia and infact 
cause death at the molecular level by this mechanism.
However, the initial biochemical changes in a poisoning 
can be totally different from those .in a natural death 
even though^they both may lead to the same critical 
events. If the initial changes in the poisoning are
persistent they may be of use in distinguishing between 
a natural and unnatural death.
Mclean (1971) has classified poisons into four types.
1) Non specific
"These destroy the whole environment and change 
the physiochemical system beyond the limits of 
tolerance of the organism eg strong acids, 
lipid solvents etc.
2) Reactive
These attack many chemical groups in the cell and 
so destroy function eg mustard gas.
3) Specific Site
These combine with specific sites to block
function and provide some of the clearest
explanations of toxicity eg fluorocitrate
blocking aconitase function, a classic biochemical 
lesion (Peters, 1963).
4) Lethal Synthesis
This group comprises those'compounds which 
were themselves inert but undergo lethal 
synthesis eg fluoroacetate which is converted 
to fluorocitrate.
The first and second group of poisons are more likely to 
produce structural changes in body tissues, which can be 
indications of overdosage, than the last two groups, which 
even in fatal cases produce structural changes that are 
usually minimal and non specific. Examples of group 1 and
2 poisoning are the brown-grey hue of methaemoglobin 
produced for instance by chlorate, skin pigmentation and 
hyperkeratosis of arsenical poisoning, hair loss of 
thallium poisoning and acute inflammation of oesophagus 
and stomach caused by irritant poisons such as ammonia 
(Gee, 1974). However, a few of group 3 and 4 poisons may . 
be detectable from examination of the body, eg pink post 
mortem staining in carbon monoxide poisoning, liver 
necrosis after a slow death from paracetamol poisoning 
(Davidson and Eastham, 1966). Others of these poisons may 
produce microscopic changes eg an acute hepatitis due to 
halothane, infiltration of eosinophils distinguishing this 
imflammatory response from hepatitis due to an infective 
agent (Johnston and Mendelsohn, 1971). Kodagoda et al.
(1973) stated that the pulmonary changes due to paraquat 
are characteristic.
Even if the potential poisons can be detected, 
levels have to be .interpreted. Interpretation is a complex 
procedure as one has to take into account extraction 
efficiencies, metabolism of compounds and interaction with 
other endogenous or ingested materials. The difference in 
susceptibility of individuals to drugs eg in children, men, 
women and the elderly has also to be considered. The 
aim of this research project was to aid interpretation 
by showing that a particular drug was having an 
effect and if possible a fatal effect. The experiments 
were designed mainly to aid in the interpretation of 
overdoses of CNS stimulants and depressants as these
compounds represent the major classes of fatal poisons 
encountered. If one considers the General Registrar’s 
Office list of fatal poisons in 1969, 1971 and 1973 >
approximately two-thirds of all the cases presented 
involved CNS depressants or stimulants ingested singly or 
in combination.
In order to choose possible biochemical changes which 
might act as overdosage markers one could consider how CNS 
stimulants or depressants act and, therefore, how these 
effects would be manifested in overdosage. Other criteria 
are that these effects have to be relatively different to 
normal post mortem biochemical changes and resistant to 
post mortem alteration. However, the detailed action of 
CNS stimulants or depressants is not known and only
*
hypotheses that apply general principles exist. At the
present time most of these hypotheses are too vague to be of
use in.practise. in the case of one class of
antidepressant drugs, the monoamine oxidase inhibitors,
increased brain amine levels may be of use in the diagnosis
of overdosage. An alternative approach is to consider .
endogenous metabolites whose levels reflect CNS activity.
There are indications that several of these compounds exist 
and include cyclic AMP, possibly cyclic GMP, noradrenaline,
5 hydroxytryptamine and dopamine, all of which are 
transmitter substances. On a more general level glucaric 
acid may be of use. This appears in the urine 
as the 1,4 lactone^ Its level is an indication of liver 
detoxifying enzyme activity and may therefore be significantly 
increased in drug overdosage.
Post mortem decay is a major problem with these 
compounds. Substances in extracellular fluids, eg urine,
CSF or vitreous humour, would be initially protected from 
autolysis. However, in some cases they might be rapidly 
attacked by invading bacteria, eg in the bladder where 
after death the sphincters are open and thus bacteria 
present in the urethra can readily enter. Conditions of 
storage of bodies, organs or extracellular fluids will 
therefore-be critical.
This research project was designed to evaluate the 
use of the first of these possible biochemical markers ie 
cyclic AMP.
Cyclic AMP in Post Mortem Urine Samples
(a) Natural deaths
It was obviously disturbing to find that in 11 of the 
26 post mortem urine samples from natural deaths 
cyclic AMP levels decreased on storage (Table 22 p 98). 
It must be noted however, that this first batch of 
samples was not treated with the inhibitor tablet.
All these post mortem urine samples contained a small 
quantity of blood, detected by its action on a blood 
test paper (Bili-labstix, Miles Laboratories) which 
was dipped in the urine. The urine sample was 
probably contaminated with blood during the sampling 
procedure from the bladder. The level of blood 
detected was equivalent to 5 - 50yl of fresh blood 
in 20ml of urine. Therefore, the effect of this 
concentration of blood on .the cyclic AMP level in 
urine was examined, Table 20 (p 94) shows that 
this quantity of blood had no effect on the level of
cyclic. AMP in the 5 urines examined (JL- hours 
incubation at room temperature). Blood has been 
shown to exhibit phosphodiesterase activity (of 
the order 0.5nmols cyclic AMP hydrolysed/min/O.lml; 
Song and Cheung, 1971). This lack of breakdown may 
be due to
(1) the low pH values of the urine samples 
ie 5.3 to 6,0 as compared with an 
optimum phosphodiesterase activity of 
' 7.4;
(ii) low metal ion concentration;
(iii) low storage temperatures.
Another possible reason for the decreasing cyclic 
AMP level could be bacterial contamination. It was, 
therefore, decided to add a phenyl mercuric nitrate 
sodium fluoride tablet to all subsequent post mortem 
urine samples to act as a bacteriostat and phosphodiesterase 
inhibitor. The tablet shows a marked inhibition of 
phosphodiesterase activity during optimum conditions 
for enzyme action (Table 21 p96 ) and would therefore 
be expected to prevent enzyme action in the relatively 
unfavourable environment of urine.
In Table 22 (p 98 ) 2 male subjects had cyclic 
AMP to creatinine ratios which were below the lower 
end of the normal male range ie 1.1 and 0.8nmols/mg 
and 1 woman's ratio was below and 1 above the normal 
female ratio range, viz 1.5 and 8.1nmols/mg. The 
women with the high ratio figure died of 
hypertensive heart disease which may be accompanied 
by an increase in cyclic AMP excretion. The low 
levels could be explained by an absence of inhibitor.
After the addition of an inhibitor tablet 
(Table 23 p 190 ) 20 (15 male' and 5 female)
out of the 40 natural death urines, were associ­
ated with cyclic AMP to creatinine ratios out­
side the normal ranges for men or women (ie 1.3
t'
to 4.5 and 2.1 to 6.6nmols cyclic AMP/mg of 
creatinine respectively). The ratios varied 
between 0.8 to 8.0nmols/mg for women and 0 to 
6.3nmols/mg for men (a 9.6nmols/mg value was 
excluded as this wis subsequently found to be a 
ratio derived from a 3 year old child).
The deaths were classified by the patholo­
gist as Fast or Slow (p 99 ) designated "F"
and "S" respectively. No correlation occurred 
between a fast or slow death and either a raised 
or lowered cyclic AMP to creatinine ratio. 
Several subjects died of hypertensive heart 
disease, however, as distinct from the previous 
subject mentioned, there were no significant 
increases in the cyclic AMP to creatinine ratio.
In contrast to the previous batch of post 
mortem urines (Table 22), which did not contain 
any preservative, all the cyclic AMP concentra­
tions in Table 23 were reproducible on reassay. 
The cause of the decreasing cyclic AMP levels 
was probably associated with bacterial action 
in the absence of inhibitor. As the cyclic 
AMP to creatinine ratios in Tables 22 and 23
showed no tendency to decrease on reassay it is 
reasonable to assume that these accurately 
reflect the ratio at the time of the post mortem 
examination. The low cyclic AMP to creatinine 
ratios observed in these cases could be due to 
bacterial action which occurred between the time 
of death and the post mortem examination’. This 
would, however, be unexpected as experiments so 
far (in vitro and in isolated bladders, Tables 7 
and 8 p 64, 67 , ) indicate that cyclic AMP
would be stable in the urine. The results 
obtained are considered on the basis of only 
limited change after death. Animal experiments 
might throw more light on this aspect of stabil­
ity in the cadaver, but such simulations are not 
without problems.
From Tables 22 and 23 the mean cyclic AMP 
to creatinine ratio in the post mortem urines 
of 42 men was 2.4nmols/mg (coefficient of varia­
tion 69%), and for 13 women 3.6nmols/mg (coef­
ficient of variation 75%). Neither of these 
means are significantly different (5% level*) 
from those found in the urines of the living. 
They do, however, show much greater scatter, ie 
over twice the coefficient of variation (see 
Section 4.10 :P .73),
* Students t’test
The greater number of low cyclic AMP to 
creatinine ratios occurring in post mortem urines 
than in controls could be due to either low levels 
of cyclic AMP in the ultimate urine sample or from 
bacterial decomposition after death. If the former 
applies there is the possibility of correlation with 
reduced CNS*, hormonal and metabolic activity in the 
dying state.
The significantly higher ratios in Table 23 are 
more difficult to explain. There is the possibility 
in old age of a reduced creatinine excretion, ie in 
the 60 - 80 age group by approximately one fifth 
(Van Pilsum and Seljeskog, 1958), which would result 
in an increased ratio figure.
Three of the six higher values listed in Table 23 
are associated with brain damage. One of these, a child 
of three years of age, was within the normal range for 
this age group. The other two had head injuries 
that proved fatal. The results of Hammadah et al.
(1972) suggested that electric shock can lead to a 
transient increase in cyclic AMP to several times that 
of the normal level. Thus the trauma of cerebral 
laceration may create a similar situation to electric 
shock,leading to raised urinary excretion of cyclic 
AMP and in increased ratio.
Cyclic AMP to creatinine ratio in drug overdose cases
In Table 24 (p 103 ) 44% (24) of the 55 drug 
deaths were outside the normal ratio variation range 
for men and women as compared with 50% in non-drug 
deaths. The drugs listed appeared on the death
certificates as the cause of death.
The deaths were also classified in terms of 
the length of time which elapsed between the subject 
being last seen alive and the discovery of the body. 
The asterisk classification (Table 24) means that 
the body was discovered within 48 hours of death, 
an ”0” classification means that a greater time period 
than 48 hours elapsed and a question mark indicates 
that the information was not available. Forty deaths 
occurred in the asterisk category, 5 in the ”0" and 
10 in the unknown category. The reason for this 
classification was to take into consideration the 
length of time the body had been decomposing before 
discovery. There is no obvious correlation between 
the time taken to detect the body and the ratio 
value. Prolonged decomposition would be expected 
to lower cyclic AMP rather than creatinine leading 
to a low ratio. Therefore more credence is given to 
ratio values obtained from urine samples isolated 
from bodies detected within 48 hours of death.
Fourteen of the. 18 drug deaths associated with 
significantly low ratio figures involved either 
hypnotics or tranquillisers (Tables 24 and 26 p 153). 
Aspirin and phenytoin caused 3 of the remaining 
deaths. The fourth death was due to natural causes.
If only the low ratios obtained from bodies discovered 
within 48 hours of death are considered, hypnotic and 
tranquilliser overdoses were associated with 9 out 
of 11 of these deaths. However, 11 deaths in the 
normal range and 4 deaths in the high ratio range were 
associated with hypnotic or tranquilliser overdoses.
* Initially listed as a drug overdose
Table 26
Drug Death Classification and the Associated 
Cyclic AMP' to Creatinine Ratio
Drug Class LowRatio
Normal
Ratio
High
Ratio
Hypnotic Tranquilliser 
plus alcohol
5 (9) 
2 (3)
9 (12) ; 
2 (4)
3
1
Anti’de'pressant 2 (3) 1
Analgesic
plus alcohol
1 (2) 3 (4) 
1
Antidepressant Hypnotic 1
*
Analgesic Hypnotic 1
Anticonvulsant 1
Antihistamine 1
Pesticide 1
Antimalarial 1
Cyanide 1
Male and Female Results Combined.
Five deaths were-associated with therapeutic levels of 
drugs and were excluded.
The numbers in parenthesis include the deaths in which
the time elapsed between death and detection of the
body was greater than 48 hours or unknown.
High cyclic AMP to creatine ratios drug 
deaths in men were associated with- an antide­
pressant,, a tranquilliser and 2 hypnotic over­
doses. In women a high ratio was associated 
with a therapeutic combination of an antide­
pressant and hypnotic and also a hypnotic death 
in which the woman suffered from nervous dis­
orders, which in themselves could affect the 
cyclic AMP to creatinine ratio. Since 2 
antidepressant deaths were also associated with 
a normal ratio, Table 26 shows that no correla­
tion occurs between an antidepressant or hypnot 
tranquilliser drug death and either a raised or 
lowered cyclic AMP to creatinine ratio.
The drug death cyclic AMP to creatinine 
ratios varied between 0.01 to 7.6nmo1s/mg for 
men and 0.01 to 7.2nmols/mg for women. The 
mean ratio for men was 2.5nmols/mg (coefficient 
of variation 73%) and for women 2.9nmols/mg 
(coefficient of variation 77%). These are not 
significantly different (5% level*) from the 
mean values occurring in natural deaths. The 
coefficients.of variation were also similar in 
both classes (73% and 77%, as compared with 69% 
and 75%).
* Students t test.
A urinary cyclic AMP/cyclic GMP ratio has not been 
considered but might be worth investigating. However,
Murad and Pak (1972) have shown a considerable and 
apparently patternless variation in urinary cyclic GMP 
levels. The considerable phosphodiesterase activity in 
blood would be expected to cause the rapid loss of both 
cyclic AMP and GMP post mortem. CSF levels of either cyclic 
AMP, cyclic GMP or a ratio of the' two, being more closely 
associated with the CNS, might prove to be effective markers. 
However, both Robison et al. (1970) and Crammer et al. (1972) 
found that CSF levels of cyclic AMP could not be correlated 
with depression or mania. Although cyclic nucleotides may 
survive longer in CSF than in blood,there is phosphodiesterase 
activity in CSF (Hidaka et al., 1974) which would lead to 
degradation. Other problems associated with the CSF will be 
dealt with in the next subsection on neurotransmitters.
The next series of possible markers of CNS activity are the 
biogenic amines, including noradrenaline, 5 hydroxytryptamine 
and dopamine. The catecholamine hypothesis of affective 
disorders postulates that behavioural depression may be 
related to a deficiency of catecholamines, usually 
noradrenaline, at functionally important central adrenergic 
receptors. The three major classes of drugs used to treat 
depression appear to interact with .catecholamines in a way 
which is consistent with this hypothesis.
1) Psychomotor stimulants eg amphetamine, mimic 
noradrenaline at the receptor, inhibit 
catecholamine reuptake, inhibit monoamine oxidase, 
displace noradrendline and release it onto the 
receptor.
2) Tricyclic antidepressants eg imipramine, 
inhibit the catecholamine axonal membrane pump 
and so increase catecholamine concentration
at the receptor.
3) Monoamine oxidase inhibitors eg phenelzine, 
prevent brain amine oxidation.
In contrast, reserpine a potent tranquilliser causes 
a depletion of brain amines and produces a depressed state 
even leading to suicidal tendencies. This situation 
at.the receptor site may be reflected by gross levels in 
brain tissue, with a rise in amine levels after ingestion of 
CNS stimulants or antidepressants, or a drop after CNS 
depressants or tranquillisers.
Raised brain amine levels have been demonstrated after 
ingestion of monoamine oxidase inhibitors. Dopamine, 
noradrenaline and 5 hydroxytryptamine levels increased in 
caudate nucleus, hypothalamus and brain stem respectively. 
(Mclean et al., 1965; Bevan-Jones et al., 1972). In 
overdose cases these increases may be considerably larger. 
Joyce (1962) observed that little change occurred in brain 
5-hydroxytryptamine during the first 48 hours after death, 
provided that the brain remained in situ. In contrast, once 
the brain was removed from the skull the 5-hydroxytryptamine 
level fell rapidly unless the brain was cooled to -17°C. 
However, I was unable to detect amines in the previously 
mentioned areas of the brain. Tissue was rapidly removed at 
autopsy and stored in a deep freeze for a week or more before 
analysis. This storage time was longer than that used by 
the previously cited authors and may account for my inability 
to repeat their findings.
Moir et al. (1970) in experiments with dogs have shown 
that the CSF concentrations of 'the cerebral metabolites of 
5 hydroxytryptamine and dopamine, ie 5 HIAA and HVA 
respectively, can be directly related to the levels of the 
metabolites in brain. The choice of brain region and CSF 
sampling site influenced the results obtained. Thus the 
levels of HVA and SHIAA in the caudate nucleus were compared 
with the CSF levels in the lateral ventricle. Similarly 
5HIAA levels in the brain stem were compared with those in 
cisternal magna CSF. One problem associated with measuring 
acid metabolites in the CSF is the existence of excretion 
systems. A saturable transport system in the fourth 
ventricle removed both HVA and 5HIAA, Other reported methods 
of removal of these acids from CSF were diffusion and bulk 
flow (Moir et al., 1970).
However, Ashcroft et al. (1966), Dencker (1966) and 
Johanssen and Roos (1967) have all shown marked differences 
in the 5HIAA and HVA levels in lumbar CSF between control, 
Parkinsonian and depressed subjects. Furthermore, Moir et al. 
(1970) showed that chlorpromazine could produce marked rises 
in these acids in the lateral ventricular CSF in dogs. 
Therefore,it may be possible to find significant changes in 
the concentration of these acids in human CSF after 
overdosage.
The fact'that many drugs increase the production of 
enzymes that detoxify them has long been known (Conney,
1957; Remmer, 1959). Among the enzymes a very important 
group are the mixed function oxidases in the liver 
endoplasmic reticulum that depend on NADPH and cytochrome
P 450, The degree of activity of this system may be 
estimated by determining D giucaric acid as its 1-4 
lactone in urine (Marsh and Reed, 1963).. March et al.
(1974) indicated that unmedicated healthy persons of 
either sex, at any age excreted giucaric acid in a highly 
consistent proportionality to creatinine. Even though 
diet can stimulate these enzymes (Mclean, 1971) more 
excretion and stability studies- may indicate that the 
level of this compound in the urine can correlate with 
drug poisoning or overdosage.
If this search for markers is fruitful it would enable 
one to show that drugs have had an effect, and possibly 
the extent of the effect ie toxic or fatal.
This would be in contrast to the present situation 
in which the effect is simply extrapolated from the amount 
of drug detected.
5.5 Clinical Application of Cyclic AMP
The cyclic AMP excretion data, which does not appear to 
have a forensic application, could well be of use in 
clinical investigation, particularly in the field of 
endocrine disorders. There is a need to establish base­
lines, ie levels normally excreted, and factors such as 
diet and exercise which may affect the baselines. The 
results obtained in this study supply some of these data. 
Information has been obtained on drug interactions 
with the bovine adrenal assay, the stability of cyclic 
AMP in urine and the establishment of a suitable 
preservative, the consistency of cyclic AMP excretion 
in the normal individual, the normal ranges.for
the cyclic AMP creatinine ratio for men and women,and the 
variation of cyclic AMP excretion with urinary flow rate, 
pH, exercise, the ingestion of vitamin C, alcohol and 
various therapeutic doses of drugs. Cyclic AMP excretion 
was little influenced by the physiological factors and 
therapeutic doses o,f drugs investigated.
Considering the vast amount of knowledge generated 
over the last two decades concerning cyclic AMP, only a 
relatively small amount has been clinically applied. Murad
(1973) suggested that this knowledge might be useful in several 
areas of investigation,
1) diagnosing endocrine and metabolic disorders,
2) understanding the cause of these disorders,
3) evaluating the effect of medical or 
surgical therapy on the patient,
4) formulating and testing new pharmacological 
preparations.
One methodological problem is the choice of fluids or 
tissues which should be used in this investigation.
Urine has several advantages as a source of cyclic AMP 
for clinical studies,
a) relatively high concentration of cyclic AMP 
(micromolar),
b) ease of sampling,
c) little or no phosphodiesterase activity,
d) urine can usually be assayed directly ie 
no need for purification.
Plasma also presents a ready source of cyclic AMP but 
has several disadvantages when compared to urine.
a) the concentration of nucleotide is two orders 
of magnitude lower than that in urine-
b) the sample usually needs to be processed before 
analysis. When protein binding assays are 
used, the plasma proteins usually need to be 
removed and in all cases the plasma 
phosphodiesterase has to be inactivated 
rapidly on collection eg by EDTA, theophylline 
etc. In some plasma samples stored at - 20°C 
without inhibitors, cyclic AMP levels decreased 
and this was suggested to be due to phosphod­
iesterase activity even at these low 
temperatures (O’ Pea et al., 1971)
An obvious advantage of blood over urine is that it has 
a direct relationship with tissues. Thus a transient 
variation in cyclic AMP levels may be observed readily in 
blood and not in urine. However, it must be remembered that 
cyclic AMP is rapidly removed from blood with a half-life 
of about 30 minutes (Section 2.3 p 26 ). There is not
sufficient information at present on cyclic AMP levels in 
other body tissues to make them a viable proposition (eg 
CSF, milk, saliva or semen).
Tissue biopsy samples may also prove useful for the 
detection of altered cyclic AMP levels or adenyl cyclase and
phosphodiesterase activities in diseases eg psoriasis
\
(Halprin et al., 1975) or cancer (Section 2.3 p 31 ).
However, these samples usually require more elaborate and time 
consuming preparation before analysis than either blood or 
urine.
If a 24 hourly sampling period is not used the 
possible effects of diurnal variation in both plasma and 
urinary cyclic AMP must be considered (Section 5.3 pl23).
Clinical evaluation of cyclic nucleotide excretion 
must allow for variation in kidney function and thus, if 
renal failure is suspected any values obtained need 
assessment in the light of kidney function tests.
There are several areas of clinical investigation 
where cyclic AMP measurement may be useful.
Calcium Disorders
The 24 hourly urinary excretion.of cyclic AMP in 
10 patients with hypercalcemia of non-parathyroid aetiology 
was significantly lower than that found in 16 
hyperparathyroid hypercalcemic subjects. If 5.5ymol of 
cyclic AMP per 24 hours is used as an arbitrary cut off 
point not one of the non-parathyroid hypercalcemic 
patients would be misdiagnosed. However, 25% of the 
surgically proven hyperparathyroid patients were below the 
cut off point (Dohan- et al., 1972). Lilienfeld-Toal
et al. (1974) found that infusion of parathyroid hormone into 
normal subjects caused a marked increase in cyclic AMP 
excretion, whereas primary hyperparathyroid subjects showed 
only a small increase. Thus administration of parathyroid 
hormone should differentiate between normal and hyper­
parathyroid subjects. Dohan et al. (1972) also found that 
cyclic AMP excretion was decreased after successful surgical 
correction of hyperparathyroidism. Bartley et al. (1975b) 
found normal levels of 24 hourly cyclic AMP in two hyper-: 
calcemic subjects whose hypercalcemia was related to 
hyperthyroidism or breast cancer with bone metastases. This
contrasted with their hyperparathyroid subjects who had a 
higher 24 hourly excretion of cyclic AMP than normals. 
Non-hyperparathyroid hypercalcemic subjects who excreted 
significantly less cyclic AMP than normals were suggested 
to have a decreased parathyroid hormone excretion. Bartley 
et al. (1975a) have further reported that normocalcemic 
hyperparathyroid subjects excrete significantly less■24 hourly 
cyclic AMP than hypercalcemic hyperparathyroid subjects.
In pseudohypoparathyroidism the lack of response to 
parathyroid hormone was suggested to be caused by a defective 
adenyl cyclase system (Chase and Aurbach, 1967).
Administration of parathyroid hormone did not increase urinary 
cyclic AMP in these subjects,in contrast to normal or true 
hypoparathyroid subjects. Considering the unreliability of 
the diagnosis of this disease by phosphate excretion 
(Tomlinson et al., 1974),cyclic AMP excretion would appear 
to be of value in its diagnosis, Hypoparathyroid subjects 
have been reported to have a lower 24 hourly cyclic AMP 
excretion than normal subjects (Section 2.3 p 27 ). 
Complications can,however, arise in that renal, bronchial 
and uterine carcinomas secreted a parathyroid hormone-like 
substance and could increase cyclic AMP excretion, whereas 
carcinomas involving bone metastases could be associated 
with a decreased 24 hourly cyclic AMP excretion (Bartley 
et al., 1975b).
Urinary cyclic AMP levels can therefore help in the 
diagnosis of calcium disorders, aid in understanding the 
causes of the disorders and also show changes compatible 
with successful therapy. Radioimmunoassay of parathyroid
hormone would obviously complement cyclic AMP measurements. 
The radioimmunoassay of parathyroid hormone is, however, 
difficult to set up because of the occurence of multiple 
forms' of parathyroid hormone in the circulation and the 
lack of supplies of highly purified human parathyroid
hormone (Woo and Singer, 1974).
Diabetes Insipidus •
There have been some contradictory reports on the 
effects of ADH in man (section 2.3 p 27 ), some workers
suggested that ADH administration increased cyclic AMP 
excretion yet this was not observed by others. Even though 
Raij et al. (1974) and Bell et al. (1974) disagreed on the 
effect of ADH in normal subjects (Section 5,3 p 132 ), both 
agreed that urinary cyclic AMP measurement, after ADH 
administration, could distinguish between central and 
nephrogenic diabetes insipidus subjects. In the latter, no 
change in cyclic AMP excretion was observed and it was 
suggested that, adenyl cyclase or a later component of the 
cyclic AMP system, eg the kinase or phosphodiesterase, was 
defective.
Depression and Mania
The Alteration in cyclic AMP excretion has been 
previously described in Section 2.3 (p 31 ).
Classification of patients by reference to their 24 hourly 
excretion of cyclic AMP may be possible. Since significant 
changes in the excretion of cyclic AMP were observed after 
successful therapy with drugs (Abdulla and Hamadah, 1970) 
or ECT (Hamadah et al., 1972), excretion of cyclic AMP may
be used as an indicator of an improving condition and would 
be a useful adjunct to psychiatric assessment. The
understanding of affective disorders might also be 
explicable in terms of intracellular levels of cyclic AMP, 
even if these are secondary to biogenic amine changes.
This could lead to the design of drugs for the treatment of 
these disorders which act at specific points, eg adenyl 
cyclase or phosphodiesterase, in the cyclic AMP system. 
Hypertension
In renovascular hypertension plasma cyclic AMP levels
i
were significantly higher than in normal subjects, in 
contrast to labile or stable hypertension. Upright 
posture produced no increase in urinary cyclic AMP in 
both normal subjects and renovascular hypertensives.
Whereas in labile hypertensives urinary cyclic AMP 
excretion increased in response to upright posture. In 
another type of hypertension, phaeochromocytoma, plasma 
cyclic AMP levels were the same as normal subjects between 
attacks but a very significant increase occurred during an 
attack. The measurement of urinary and plasma cyclic AMP 
could therefore be of diagnostic value in distinguishing 
between these types of hypertension, /
Poisoning by Drugs
Keatinge et al. (1975) have observed changes in^rat 
urine cyclic AMP after chronic administration of drugs. 
Reserpine (a tranquilliser) reduced the excretion of cyclic 
AMP whereas amitriptyline and imipramine (antidepressants) 
increased excretion. After poisoning by these types of drugs
characteristic changes in the plasma or urinary level of 
cyclic AMP may be observed and could therefore aid in the 
diagnosis of this type of poisoning.
Drugs affecting the cyclic AMP system when administered in 
therapeutic dosage
If the aetiology of certain diseases can be explained 
in terms of altered cyclic AMP levels, drugs that alter 
cyclic AMP levels could logically be used to treat them.
Amer and McKinney (1973) have suggested that drugs could 
be used to,
1) alter the intracellular levels of cyclic
nucleotides by affecting a) synthesis
b) degradation c) loss to extracellular 
fluid,
2) alter the intracellular activity of cyclic
nucleotides by a) drugs that mimic the 
action of cyclic nucleotides b) drugs that 
antagonise their intracellular effect,
3) alter the action of agents that affect the
cyclic AMP system, eg prostaglandins their 
derivatives or antagonists.
The measurement of cyclic nucleotides in blood 
and urine would then become important in assessing their 
action.
"Hypovase", an antihypertensive drug, which was 
specifically developed as a phosphodiesterase inhibit'or is 
a drug of this type. The increase in cyclic AMP level 
relaxes smooth muscle and decreases blood pressure (Hess, 
1974). Other drugs that either specifically inhibit
phosphodiesterase or enhance the action of cyclic AMP,, 
have been suggested as potentially useful in the 
treatment of atherosclerosis (Shimamoto et al., 1975) 
abdominal tumors (Waddel et al., 1975) and psoriasis 
(Anonymous. Shanghai Biochem Res Inst, 1974).
The measurement of cyclic AMP in body fluids can 
therefore supply useful information with which to 
diagnose, understand and aid in the treatment of many 
diseases. These measurements will become of increasing 
importance if the potential use of cyclic nucleotide 
research in clinical medicine is realised.
SECTION 6 
CONCLUSIONS
6. CONCLUSIONS
Any biochemical markers which aid the forensic scien­
tist and pathologist in the establishment of the cause of 
death are worth investigating. The body fluids which 
may be of value are those partially isolated from the 
mass of body tissue such as urine, CSF and vitreous humour. 
In this study the urinary cyclic AMP to creatinine ratio 
was chosen as the biochemical marker. - •
The urine samples from post mortem examinations
i
carried out not more than 3 days after death, should con­
tain cyclic AMP levels that relate well to the levels 
occurring at death because
(a) cyclic AMP is normally stable for 3 days in a 
urine sample stored at room temperature or in
a bladder at 4°C, and
(b) a preservative tablet, added at the post mortem 
(or as soon after as was practically possible) 
to the urine sample, will preserve cyclic AMP 
levels for at least 6 weeks at room temperature.
Before considering post mortem variation it is neces­
sary to establish variation in life. The study shows 
that the normal cyclic AMP to creatinine ratios for a 
male and female population are 1.3 - 4.5nmols/mg and 2.1- 
6.6nmols/mg respectively; cyclic AMP is consistently 
excreted (24 hourly coefficients of variation 7% and 14%), 
showing only a slight diurnal variation, by the two sub­
jects studied; a variety of conditions including change
of. urine flow rate, urine pH, exercise, intake of alcohol
or vitamin C and ingestion of therapeutic quantities of
drugs (amphetamine, amylobarbitone, imipramine, trifluo­
perazine) do not significantly affect urinary excretion. 
Cyclic AMP is therefore consistently excreted and the 
excretion is relatively unaltered by the physiological 
factors tested or drugs ingested.
In natural deaths, even though the mean cyclic AMP 
to creatinine ratio is not significantly different (5%) 
from that of living subjects the ratio is considerably 
more variable (ie coefficients of variation are approxi­
mately 3 times greater in post mortem samples).
The original hypothesis was that in overdose quanti­
ties drugs that depressed the CNS (hypnotics and tranquil- 
isers) would, result in low urinary levels of cyclic AMP, 
whereas the reverse situation would be true for CNS stim­
ulants (antidepressant and stimulants). The results in 
Table 26 (page 153 ) show that this postulate is no longer 
tenable as the ratio gives no clear pattern in drug over­
dose deaths.
The variation in the cyclic AMP to creatinine ratio 
in drug deaths is in fact no greater than that observed 
in urines from natural deaths,, and t'his normal post mortem 
ratio variation may mask any drug effects that occur.
Therefore, the results of this investigation show 
that urinary cyclic AMP measurement has no forensic 
application. However, the present use and potential of 
urinary cyclic AMP to help in the diagnosis of, under­
standing of, and aid in the treatment of many diseases, 
demands a detailed knowledge of the variation of this 
nucleotide in both health and disease. This study supplies 
a considerable amount of this fundamental data, which can be 
used as a base for further research into the clinical value 
of cyclic AMP measurement.
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APPENDICES
APPENDIX la
The Best Estimate of the Standard Deviation of a Population 
If a sample is small (n = 30 or less) its standard
A
deviation S can no longer be used as an approximation of 
the standard deviation of a population. Since in general 
a.population will contain more extreme data than a sample 
it is to be expected that the standard deviation of the
A .
population S will be some what larger than S. It is 
impossible to write- a precise formula for S in terms of S 
since different samples of a population may have widely 
differing standard deviations. In most cases however the 
quantity •
will give an excellent approximation of S though it will 
be rarely precisely equal to S (n = number of determinations) 
eg, in case of interassay deviation the best estimate of the 
standard deviation.
= / f ” * (n = 8, page 56)
/I7I4. 10%
1.07 . 10%
10.7%
APPENDIX lb
Linear Regression Equation
If there is a linear relationship between 2 variables 
X and Y the equation of the line relating X and Y is 
. . Y =.a + bX ..... (1)
where "a" is the point of intercept of the.Y axis and "b" 
is the slope of the line.
If a series of X and Y values are.known the'best
straight line is constructed by using the above equation
\i
(1), and determining the minimum value for £(Yo - Ye)2 
where Yo is the value of Y actually obtained and Ye is the 
expected value of Y. The problem has been reduced to 
finding for a given sample of n pairs of values X and Y 
the constants "a" and "bM of equation (1) using differential 
calculus
an t b Z X — EY ...... (2)
a EX + b EX2 = EXY --- - (3)
solving for b
b = n EXY - IXEY . .
nEX2 - (EX)2
as X = —  Y = —  b ='£XY -
n . . “ T.X - n X 2
substitute in equation (1) for MaM once "b" has been 
calculated.
The line Ye = a + bX which has been fitted to a set 
of n points X,Y by the method of least squares is called 
the line of regression of Y on X or line of prediction of 
Y. The Hewlett Packard 9100 desk calculator has a program 
which provides the constants "a" and "bM. and has been 
regularly used for constructing cyclic AMP standard curves.
MXM represents the nucleotide concentration and "Y" the 
ratio of the total amount of tritiafed cyclic AMP to the 
amount of bound tritiated cyclic AMP respectively.
The standard curve is only normally used between the 
values of 10 and 25 (figure 8). Low ratio values tend 
to be inaccurate as they represent very low nucleotide 
concentrations which are near the limit of sensitivity of 
the assay. On the other hand high ratio values tend to 
be inaccurate as they represent such small count rates 
that alterations in the background become significant. 
However, high ratio values, ie above 25, are extremely 
useful in that they are usually accurate enough to provide 
a correct dilution factor with which to bring the cyclic 
AMP concentration in the sample onto the usable part of 
the graph.
APPENDIX 1c
Correlation Between Urine Flow Rate and Cyclic AMP 
Excretion
Subjects I and II’s correlation ' coefficients were. 
0.16 and -0.16 respectively, and from two populations 
with correlation coefficients of zero, samples of 51 
(Subject II) and 29 (Subject I) pairs with correlation 
coefficients of -0.16 or 0.16 are obtained more than 
10% of the time. This would suggest that there is no
t/
significant correlation between urine flow rate and 
cyclic AMP excretion.
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indeed the dose-related inhibition curves were almost 
identical.
T he results o f  this brief study clearly indicate that no 
differences exist between the effects o f  heparins from  
different tissue sources on plasma-lysolecithiu formation 
and on collagen-induced platelet aggregation in man. N o  
obvious differences in anticoagulant activity in man have 
been reported,4-s and it seems that ox-lung and hog- 
mucosa heparins have the same biological activity even 
though their neutralisation by protamine sulphate may 
show a significant difference.
24- h o t i r l y  c  y c l i c - a . m . p .  r x c R ir r io N  a n d  u r i n e  v o l u m e
Department of Cardiology, 
St. Mary’s Hospital, 
London W2 1NY.
M . P. T . G i l l e t t  
E. M . M . Bf.sterm an.
V A R IA T IO N  O F  C Y C L IC -A .M .P . E X C R E T IO N  
W IT H  U R IN E  V O L U M E
S ir,— If  the measurement of.urinary cyclic a.m .p . levels 
is to be o f clinical significance ^  it is important to ensure 
that urine flow-rate does not affect the excretion o f  cyclic 
A.M.P. Several previous reports, however, have indicated 
that urine volume affects cyclic-A.M.P. excretion. Taka- 
hashi et al.3 reported that water loading decreased urinary 
cyclic a .m .p . excretion, a result inconsistent w ith a later
s s  ,
*8!KEFU* RATE
Change in  th e  rate o f cyclic-A .M .P . excretion  w ith  urinary flow - 
rate.
(Subject PO ACM O .)
paper 4 which suggested that the increased cyclic-A.M.p. 
excretion o f  manic patients was partially due to their con­
sistently increased urine volume. Both reports contrast 
.with the experimental results in  rats 5 and dogs,6 in which 
extreme variations in  urine flow-rate have had a negligible 
effect on cyclic-A.M.p. excretion.
Using a protein-binding a ssay7 we have completed 
several studies to determine the effect o f change in  urine 
volume on cyclic-A.M.p. excretion in man. During the 
experiment, normal male subjects had their exercise and 
tea and coffee intake controlled. W hen the urine flow-rates 
for two individuals were plotted against cyclic-A.M.p. 
excretion rates (see figure), no significant correlation be-
1. Abdulla, Y. H., Hamadah, K. Lancet, 1970, i, 378.
2. Taylor, A. L., Davies, B. B., Pawlson, L. G., Josmiovich, J. B.,
Mintz, D . H. J. clin. Endocr. 1970, 30, 316.
3. Takahashi, K., Kamimura, M., Shinko, T ., Tsuji, S. Lancet, 1966,
ii, 967.
4. Paul, M. I., Cramer, H ., Goodwin, F. K. ibid. 1970, i, 986.
5. Hardman, J. G., Davis, J. W., Sutherland, E. W. J . biol. Chem.
1969, 244, 6354.
6. Goldberg, N . D ., Latncr, J., Sasko, H., O’Toole, A. G. Anal.
Biochem. 1969, 28, 523.
7. Brown, B. L., Albano, J. D . M ., Ekins, R. P., Sgherzi, A. M.
Biochem. J . 1971, 121, 561.
Normal Water-loaded
Subject Cyclic Urine Cyclic Urine
A.M.P. volume A.M.l’. volume
(nmol) (ml.) (nmol) (ml.)
ACM 301 1220 2-55 3360
DAP 4-03 820 5-21 1170
ERR 2-73 1575 2-90 4100
PO 4-53 1245 3-76 3120'
T SH 5-59 1805 5-17 4420
tween the two rates was observed (subject AC M , r — 
+ 0-163, subject PO, r — —0-161), even though there was an 
extreme variation in urine flow-rate (i.e., 0-15-8-4 ml. per 
m in.). In addition, 24-hourly urine samples were collected 
from a group o f five subjects under (a) normal and (b) 
water-loaded conditions (see table). Although there was 
an increase in  urinary output in all cases, three subjects 
showed a net decrease in 24-hourly cyclic-A.M.p. excretion 
and two showed an increase. As the coefficients o f  variation 
in the 24-hourly excretion o f  cyclic a.m.p. over several 
weeks were found to be ±22%  and ± 14%  for subjects 
PO and ACM , respectively, the indication is that the 
subjects in  the table are showing a normal variation.
Thus doubling or almost trebling urine volume over the 
24-hour period resulted in no consistent or significant 
change in the excretion o f cyclic a.m.p. Urine volume is 
therefore not one o f the physiological factors which deter­
mines the urinary excretion o f cyclic a.m.p. in man.
Home Office Central 
Research Establishment, 
Aldcrmaston, Reading, 
Berks RG7 4PN.
P. O wen 
A. C. M offat.
MULTIPLE MYELOMA AND RENAL 
IMPAIRMENT
S ir ,— It is estimated that 30-50%  o f  all m ultiple- 
myeloma patients have some degree o f  renal im pairm ent.1 
Although it has been suggested that Bencc Jones proteinuria 
may be related to the onset o f  renal involvem ent, as yet 
no mechanism has been unambiguously demonstrated. 
In an effort to determine the factors resulting in acute 
renal failure in such instances, we are chemically and 
physically characterising purified species (monomers, 
dimers, and higher aggregates) o f  Bence Jones protein from  
patients with and without renal complications.
Based upon the repeated finding at necropsy or biopsy  
o f  proteinaceous casts rich in  Bence Jones protein in the  
renal tubules li2 and the pH -dependent solubility o f  Bence  
Jones protein,3-it has been hypothesised that, under con­
ditions promoting urine concentration and acidification, 
precipitation o f  Bence Jones protein may occur in the  
nephrons, thus producing acute renal failure in the m yeloma 
patient. Accordingly, it has been proposed 4 that sodium  
bicarbonate and acetazolamide may be useful in the pre­
vention and treatment o f  this problem. T his is em phasised  
by our findings on the Bence Jones protein (3 -7  m g. per 
ml. urine) from a patient w ith acute renal failure (urine 
output o f  0-150  ml. per day and serum creatinine o f  23 mg. 
per 100 m l.) which ameliorated (urine output greater than 1 
1. per day and serum creatinine o f  6 mg. per 100 m l.) 
after nearly two m onths o f  hem odialysis and treatment 
with alkeran, sodium bicarbonate, and prednisone. Open  
biopsy o f  a wedge o f  kidney showed a grossly normal kidney, 
but striking histological findings o f  tubular lum ens filled
1. Hcptinstali, R. H. Pathology of the Kidney. Boston, 1966.
2. Bryan, C. W., Hcaly, J. K. Am.jf. Med. 1968, 44, 128.
3. Putnam, F. W., et al. Archs Biochem. Biophys. 1959, 83, 115.
4. Rees, E. D ., Waugh, W. H. Archs intern. M ed. 1965, 116, 400.
Toxicologie experimentale
Inhibition in vitro 
of cyclic 3 ',5 ' nucleotide 
phosphodiesterase activity by drugs
A.C. M o f f a t, D.A. Pa tterson, A.S. C urry and P. O w e n
H om e Office Central Research Establishm ent A lderm aston, Reading, Berks (Great Britain).
R esume
L’effet inhibiteur de 70 medicaments sur la 3, 5, nucleotide cyclique-phosphodiesterase du coeur de bceuf, a ete 
etudie in vitro. La trifluoperazine, la chlorpromazine, la triflupromazine, la picrotoxine, le A,,-tetrahydro­
cannabinol, I’ergotsmine, la papaverine et l’acide ascorbique ont montre une action inhibitrice a une concen­
tration de 1.1 O'4 M, mais aucun effet n’a ete observe a 1.1 O'5 M. 31 composes n’ont pas montre d’effet 
inhibiteur a une concentration de 1.10'2 M.
M anuscrit regtt le 25 fevrier 1972.
Introduction
Cyclic 3'-5'-adenosine monophosphate (cyclic 
AMP) is now known to mediate the action of 
a number of hormones and is therefore invol­
ved in the modulation of certains types of cell 
activity. Its immediate precursor in the body is 
adenosine triphosphate (ATP) and its catabo- 
lite is 5'-adenosine monophosphate (5'-AMP). 
The latter is formed in the presence of the 
hydrolytic enzyme 3'-5'-cyclic nucleotide phos­
phodiesterase (PDE).
A  severe fall in the concentration of cyclic 
AMP in the cells, including those of the central 
nervous system, has been postulated to account 
for depressive illness [1], [2], [3] and it has 
also been suggested that some antidepressant 
drugs may produce their effect by the inhibi­
tion of PDE4, thus allowing the concentration 
of cyclic AMP in the cells to return to a 
”normal“ level. Further, cyclic AMP is excre­
ted by glomerular filtration and its concentra­
tion in the urine has been claimed to reflect 
the clinical status of depression or mania [2].
If these observations are correct the implications 
for the chemical pathologist are important, for 
a quantitative cyclic-AMP determination on 
the urine taken at post-mortem could provide 
evidence of the state of mind before death. 
However, a number of factors could alter the
rate of excretion of the compound and hence 
complicate the interpretation of the results of 
such determinations. The effects of medication, 
exercise and diet are being investigated in this 
laboratory.
This paper deals with some preliminary experi­
ments in which a large number of drugs with 
a wide range of pharmacological actions have 
been screened for in vitro  PDE inhibitory acti­
vity. Those drugs which are highly active will 
of course be of particular interest in later in 
vivo  studies.
Experimental
For each drug tested, six reaction mixtures 
comprising three tests and three controls were, 
prepared. Each of the test mixtures contained 
cyclic AM P (0.15 jx mole), Tris buffer, 
pH 7.5. (8.0 p mole), magnesium sulphate 
(0.4 [x mole), enzyme (0.01, 0.005 or 0.0025  
units, from beef heart, Sigma Chemical Com­
pany) and drug or drug salt in a total volume 
of 200 pi. The control mixtures were iden­
tical, but with the drug omitted. The enzyme 
concentrations chosen were those necessary to 
convert approximately 50, 25 and 12% respec­
tively of the cyclic AMP present to 5'-AMP 
after an incubation period of 1 hour at 37 °C. 
The reactions were subsequently stopped by- 
immersion of the tubes in ice.
TABLE I
Inhibition of cyclic AM P phosphodiesterase from beef heart by drugs
Drug
Minimum Inhibitory* 
Concentration 
(molar)
Trifluoperazine hydrochloride*
Chlorpromazine hydrochloride
Trifiupromazine hydrochloride
Picrotoxin
A9-Tetrahydrocannabinol 1 X 10-4
Ergotamine tartrate*
Papaverine hydrochloride*
L-Ascorbic acid
Phenelzine acid sulphate
Pargyline hydrochloride
Imipramine hydrochloride
Nortriptyline hydrochloride
Amitriptyline hydrochloride
Desipramine hydrochloride
Methaqualone hydrochloride*
Serotonin creatinine sulphate
Theophylline 1 x  IO- 3
Pentazocine hydrochloride
Lysergide acid tartrate
Ibogaine hydrochloride
Nalorphine hydrobromide
Salicylic acid
Phenylbutazone*
Dextromethorphan hydrobromide
Chlordiazepoxide*+
Chlordia 3 epoxide*^
Caffeine
Codeine phosphate
Methadone hydrochloride
Ethoheptazine citrate+
Paracetamol
Acetylsalicylic acid+
Mescaline hydrochloride 1 x  lO-2
A8-Tetrahydrocannabinol*
Mepyramine maleate+
Promethazine hydrochloride*
Histamine dihydrochloride+
Tetracycline hydrochloride*+
Strychnine hydrochloride*
Reserpine*
Diazepam*
Nitrazepam*
Oxazepam*
Meprobamate
Haloperidol*
Glutethimide
Carbromal*
Chloral hydrate
Ethyl alcohol
Adrenaline*
Amphetamine sulphate
Methylamphetamine hydrochloride
Ephedrine hydrochloride
Fenfluramine hydrochloride
Isoprenaline hydrochloride N o  activity at
Diethylpropion hydrochloride 1 X lO"2
Phenmetrazine hydrochloride
Nikethamide
Diamorphine hydrochloride
Morphine sulphate
Pethidine hydrochloride
Propoxyphene hydrochloride*
Cocaine hydrochloride
Atropine sulphate
Benzocaine*
Lignocaine hydrochloride
Diphenhydramine hydrochloride
Antazoline hydrochloride
Methyldopa
Pyridoxine hydrochloride
Nicotinamide
* N o t so luble a t th a t co ncen tra tion
-f- pH  of the reac tion  m ix tu re altered  by th e  drug
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Aliquots (10 fxl), were then spotted onto 
Eastman Chromagram cellulose sheets (100 p) 
and developed in a solvent system composed of 
n-bulanol-acetone-acetic acid-5 % ammonium 
hydroxide-water (45 4-15 +  10 +  10 +  20) [5], 
which separated the two nucleotides from one 
another and from the drugs, (Rf values : cyclic 
AMP, 0.41; 5'-AMP, 0.25). The chromato­
grams were examined under U V  light (254 nm) 
and the densities of the three test cyclic AMP ‘ 
spots were compared with those of the controls. 
A  clear difference in densities between the two 
series of spots was taken as an indication of 
inhibition.
Results and discussion
The results are given in table 1. Of the 70 
drugs examined, only eight were active at a
concentration of 1 X 10~4 M, and none of
these inhibited at 1 X 10-5  M. A t a
concentration of 1 X 10-2  M, seven of the
drugs caused an alteration in the pH of the 
reaction mixture and therefore an apparent 
inhibition of the' enzyme. A t lower concentra­
tions, however, this pH change was Jess than 
0.2 pH units.
A  number of drugs have previously been 
shown to inhibit PDE, reserpine [6] and the 
phenothiazines [1, 4, 7, 8] being reported 
to be most active. The methylxanthines are 
also active [9, 10, 11, 12] but the catechola­
mines and barbiturates [13] exhibit little or no 
inhibition.
In our experiments, the three most potent PDE  
inhibitors were trifluoperazine, chlorproma- 
zine and triflupromazine, all of which are 
phenothiazine tranquillisers. Other drugs used 
for the treatment of depression, eg. the mono­
amine oxidase inhibitors (phenelzine and par- 
gyline) and the dibenzazepine derivatives (imi- 
pramine, nortriptyline, amitriptyline and 
desipramine) inhibited at a concentration of 
1 X 10-3  M, but the benzodiazepines, 
meprobamate and haloperidol had low activity.
The hypnotics, sympathomimetic amines and 
analepticts, had little or no activity, with the 
exception of picrotoxin which was one of the 
most active. This is in contrast with the results 
of R oberts and Simonsen [13] who found 
that picrotoxin had no effect on PDE  
from mouse brain at a concentration of 
1 X 10 -3  M. The discrepancy is possibly due 
to differences in the source of the PDE used. 
Our results for the other stimulants examined, 
the methylxanthines, paralleled those of pre­
vious workers, theophylline being found to be 
more active than caffeine.
Of the other drugs known to have an effect 
upon the brain, the hallucinogens were more 
active than the narcotics and analgesics. 
Indeed, A °-tetrahydrocannabinol exhibited 
high activity, inhibiting PDE at the 1 X 
10- 4 M level.
Perhaps the most surprising of our results was 
the high activity of ascorbic acid. Since it is a 
normal dietary component and may also be 
taken in large therapeutic doses this substance 
will be the subject of special attention in our 
in v ivo studies.
Summary
A n in vitro  study has been made of the inhibitory 
action o f 70 drugs on beef heart cyclic 3',5'-nucleo- 
tide phosphodiesterase. Trifluoperazine, chlorproma- 
zine, triflupromazine, picrotoxin, A9-tetrahydrocan- 
nabinol, ergotamine, papaverine and ascorbic acid 
inhibited at a concentration of 1 X 10~4 M, 
although none was active at 1 X  10~5 M. At 
1 X 10~2 M, 31 drugs failed to inhibit the 
enzyme.
ZUSAMMENFASSUNG
Es wurde eine Studie in vitro  ausgefiihrt, um die 
hemmende Wirkung von 70 Arzneim itteln auf die 
zyklische 3',5'-Phosphodiesterase der Nukleotide des 
Rinderherzens zu untersuchen. Trifluoperazin, Chlor- 
promazin, Triflupromazin, Picrotoxin ' A9-Tetrahy- 
drocannabinol, Ergotamin, Papaverin und Askor- 
binsaure hemmen bei einer Konzentration von  
1 X 10~4 M, obwohl keine dieser Substanzen bei 
1 X 10~5 M aktiv war. Bei 1 X  10'2 versagte die 
Hemmung des Enzyms bei 31 Substanzen.
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